Inari Medical (NARI) 10-K 23 Feb 22 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Feb. 18, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Document Fiscal Year Focus	2021
Entity File Number	001-39293
Entity Registrant Name	Inari Medical, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-2902923
Entity Address, Address Line One	6001 Oak Canyon
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Irvine
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92618
City Area Code	877
Local Phone Number	923-4747
Title of 12(b) Security	Common stock, $0.001 par value per share
Trading Symbol	NARI
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 3,950
Entity Common Stock, Shares Outstanding		50,617,254
Entity Central Index Key	0001531048
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Amendment Flag	false
ICFR Auditor Attestation Flag	true
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE The Registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December 31, 2021. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.
Auditor Firm ID	243
Auditor Name	BDO USA, LLP
Auditor Location	Costa Mesa, California

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 92,752,000	$ 114,229,000
Short-term investments	83,348,000	49,981,000
Accounts receivable, net	42,351,000	28,008,000
Inventories, net	21,053,000	10,597,000
Prepaid expenses and other current assets	5,694,000	2,808,000
Restricted cash	0	50,000
Total current assets	245,198,000	205,673,000
Property and equipment, net	16,471,000	7,498,000
Operating lease right-of-use assets	44,909,000	0
Long-term investments	3,983,000	0
Deposits and other assets	981,000	583,000
Restricted cash	0	338,000
Total assets	311,542,000	214,092,000
Current liabilities
Accounts payable	6,541,000	3,047,000
Payroll-related accruals	24,433,000	8,198,000
Accrued expenses and other current liabilities	10,737,000	2,593,000
Operating lease liability, current portion	802,000	0
Total current liabilities	42,513,000	13,838,000
Operating lease liabilities, noncurrent portion	28,404,000	0
Other long-term liability	1,416,000	0
Total liabilities	72,333,000	13,838,000
Commitments and contingencies (Note 7)
Stockholders' equity (deficit)
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2021 and December 31, 2020	0	0
Common stock, $0.001 par value, 300,000,000 shares authorized as of December 31, 2021 and December 31 2020; 50,313,452 and 49,251,614 shares issued and outstanding as of December 31, 2021 and December 31 2020, respectively	50,000	49,000
Additional paid in capital	257,144,000	227,624,000
Accumulated other comprehensive income	(402,000)	4,000
Accumulated deficit	(17,583,000)	(27,423,000)
Total stockholders' equity	239,209,000	200,254,000
Total liabilities and stockholders' equity	$ 311,542,000	$ 214,092,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, Par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, Par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	50,313,452	49,251,614
Common stock, shares outstanding	50,313,452	49,251,614

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenue	$ 276,984	$ 139,670	$ 51,129
Cost of goods sold	24,757	13,106	5,911
Gross profit	252,227	126,564	45,218
Operating expenses
Research and development	51,018	18,399	7,220
Selling, general and administrative	190,365	89,746	37,197
Total operating expenses	241,383	108,145	44,417
Income from operations	10,844	18,419	801
Other income (expense)
Interest income	154	484	89
Interest expense	(295)	(1,135)	(920)
Change in fair value of warrant liabilities	0	(3,317)	(957)
Other expenses, net	(18)	(662)	(205)
Total other expenses	(159)	(4,630)	(1,993)
Income (loss) before income taxes	10,685	13,789	(1,192)
Total Provision for income taxes	845	0	0
Net income (loss)	9,840	13,789	(1,192)
Total other comprehensive income (loss)
Foreign currency translation adjustments	(379)	0	0
Unrealized (loss) gain on available-for-sale securities	(27)	4	0
Total other comprehensive income	(406)	4	0
Comprehensive income (loss)	$ 9,434	$ 13,793	$ (1,192)
Net income (loss) per share
Basic	$ 0.20	$ 0.43	$ (0.20)
Diluted	$ 0.18	$ 0.27	$ (0.20)
Weighted average common shares used to compute net income (loss) per share
Basic	49,815,914	32,033,827	5,887,542
Diluted	55,594,159	51,554,996	5,887,542

Consolidated Statements of Mezz

Consolidated Statements of Mezzanine Equity and Stockholders' Equity (Deficit) - USD ($)	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Subscriptions Receivable	Additional Paid In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Accumulated DeficitCumulative Effect, Period of Adoption, Adjustment	Redeemable Convertible Preferred Stock
Beginning Balance at Dec. 31, 2018									$ 54,170,000
Beginning Balance, Shares at Dec. 31, 2018									31,968,570
Balance at Dec. 31, 2018	$ (39,446,000)	$ 104,000	$ 6,000	$ (758,000)	$ 1,430,000	$ 0	$ (40,124,000)	$ 104,000
Beginning Balance, Shares at Dec. 31, 2018			6,310,865
Options exercised for common stock	127,000		$ 1,000	0	126,000	0	0		$ 0
Options exercised for common stock, Shares			409,902						0
Interest earned on subscription receivable	15,000		$ 0	15,000	0	0	0
Proceeds from subscriptions receivable	773,000		0	773,000	0	0	0
Share based compensation	505,000		0	0	505,000	0	0		$ 0
Net income (loss)	(1,192,000)		0	0	0	0	(1,192,000)		0
Ending Balance at Dec. 31, 2019									$ 54,170,000
Ending Balance, Shares at Dec. 31, 2019									31,968,570
Balance at Dec. 31, 2019	(39,144,000)		$ 7,000	0	2,061,000	0	(41,212,000)
Ending Balance, Shares at Dec. 31, 2019			6,720,767
Conversion of preferred stock to common stock upon initial public offering (IPO)	54,170,000		$ 32,000	0	54,138,000	0	0		$ 54,170,000
Conversion of preferred stock to common stock upon initial public offering (IPO) Shares			31,968,570						(31,968,570)
Issuance of common stock in connection with IPO, net of issuance costs of $16.3 million	162,979,000		$ 9,000	0	162,970,000	0	0		$ 0
Issuance of common stock in connection with IPO, net of issuance costs of $16.3 million, Shares			9,432,949						0
Conversion and reclassification of preferred stock warrants to common stock warrants upon IPO	4,486,000		$ 0	0	4,486,000	0	0		$ 0
Conversion and reclassification of preferred stock warrants to common stock warrants upon IPO, Shares			0						0
Exercise of common stock warrants	5,000		$ 1,000	0	4,000	0	0		$ 0
Exercise of common stock warrants, Shares			277,309						0
Options exercised for common stock	466,000		$ 0	0	466,000	0	0		$ 0
Options exercised for common stock, Shares			851,189						0
Issuance of common stock upon vesting of restricted stock units, net of shares with held for taxes	(25,000)		$ 0	0	(25,000)	0	0		$ 0
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for taxes, Shares			830						0
Share based compensation	3,524,000		$ 0	0	3,524,000	0	0		$ 0
Other comprehensive income (loss)	4,000		0	0	0	4,000	0		0
Net income (loss)	13,789,000		0	$ 0	0	0	13,789,000		0
Ending Balance at Dec. 31, 2020									$ 0
Ending Balance, Shares at Dec. 31, 2020									0
Balance at Dec. 31, 2020	200,254,000		$ 49,000		227,624,000	4,000	(27,423,000)
Ending Balance, Shares at Dec. 31, 2020			49,251,614
Options exercised for common stock	869,000		$ 1,000		868,000	0	0		$ 0
Options exercised for common stock, Shares			806,008						0
Issuance of common stock upon vesting of restricted stock units, net of shares with held for taxes	(2,354,000)		$ 0		(2,354,000)	0	0		$ 0
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for taxes, Shares			170,781						0
Share based compensation	25,448,000		$ 0		25,448,000	0	0		$ 0
Issuance of common stock under employee stock purchase plan	5,558,000		$ 0		5,558,000	0	0		$ 0
Issuance of common stock under employee stock purchase plan, Shares			85,049						0
Other comprehensive income (loss)	(406,000)		$ 0		0	(406,000)	0		$ 0
Net income (loss)	9,840,000		0		0	0	9,840,000		0
Ending Balance at Dec. 31, 2021									$ 0
Ending Balance, Shares at Dec. 31, 2021									0
Balance at Dec. 31, 2021	$ 239,209,000		$ 50,000		$ 257,144,000	$ (402,000)	$ (17,583,000)
Ending Balance, Shares at Dec. 31, 2021			50,313,452

Consolidated Statements of Me_2

Consolidated Statements of Mezzanine Equity and Stockholders' Equity (Deficit) (Parenthetical) $ in Millions	12 Months Ended
	Dec. 31, 2020USD ($)
Stock issuance cost	$ 16.3

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net income (loss)	$ 9,840	$ 13,789	$ (1,192)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation	3,034	1,385	614
Amortization of deferred financing costs	143	181	101
Amortization of right-of-use assets	1,274	0	0
Share based compensation expense	25,448	3,524	505
Allowance for credit losses	22	0	62
Loss on disposal of fixed assets	69	237	119
Loss on extinguishment of debt	0	648	205
Loss on change in fair value of warrant liabilities	0	3,317	957
Amortization of fair value of warrants issued with debt	0	0	14
Changes in:
Accounts receivable	(14,361)	(16,706)	(9,017)
Inventories	(10,488)	(6,644)	(2,874)
Prepaid expenses, deposits and other assets	(3,430)	(2,458)	(1,158)
Accounts payable	3,514	498	1,835
Payroll-related accruals, accrued expenses and other liabilities	25,992	4,141	4,893
Lease Prepayments For Lessor's Owned Leasehold Improvements	(14,755)	0	0
Operating lease liabilities	(772)	0	0
Net cash provided by (used in) operating activities	25,486	1,912	(4,936)
Cash flows from investing activities
Purchase of property and equipment	(13,645)	(5,460)	(3,144)
Purchase of short-term investments	(134,377)	(49,977)	0
Maturities of short-term investments	97,000	0	0
Net cash used in investing activities	(51,022)	(55,437)	(3,144)
Cash flows from financing activities
Proceeds from exercise of stock option and warrants	869	471	127
Payment of taxes related to vested restricted stock units	(2,354)	(25)	0
Proceeds from issuance of common stock upon initial public offering, net of issuance costs paid	0	164,361	0
Proceeds from notes payable	0	10,000	20,000
Repayments of notes payable	0	(30,250)	(10,140)
Debt financing costs	0	(442)	(536)
Proceeds from subscriptions receivable	0	0	772
Proceeds from issuance of common stock under employee stock purchase plan	5,558	0	0
Net cash provided by financing activities	4,073	144,115	10,223
Effect of foreign exchange rate on cash and cash equivalents	(402)	0	0
Net (decrease) increase in cash	(21,865)	90,590	2,143
Cash, cash equivalents and restricted cash beginning of period	114,617	24,027	21,884
Cash, cash equivalents and restricted cash end of period	92,752	114,617	24,027
Supplemental disclosures of cash flow information:
Cash paid for income taxes	472	154	14
Cash paid for interest	151	999	810
Noncash investing and financing:
Lease liabilities arising from obtaining right-of-use assets	28,648	0	0
Common stock issued on conversion of convertible preferred stock	0	54,170	0
Common stock warrants issued on conversion of preferred stock warrants and the reclassification of the warrant liability	0	4,486	0
Deferred initial public offering cost recorded to additional paid in capital	0	1,382	0
Accrual of deferred interest obligation associated with debt	$ 0	$ 0	$ 150

Organization

Organization	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. Organization Description of Business Inari Medical, Inc. (the “Company”) was incorporated in Delaware in July 2011 and is headquartered in Irvine, California. The Company develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Initial Public Offering In May 2020, the Company completed an initial public offering (“IPO”) of its common stock. As part of the IPO, the Company issued and sold 9,432,949 shares of its common stock, which included 1,230,384 shares sold pursuant to the exercise of the underwriters’ over-allotment option, at a public offering price of $ 19.00 per share. The Company received net proceeds of approximately $ 163.0 million from the IPO, after deducting underwriters’ discounts and commissions of $ 12.6 million and offering costs of $ 3.7 million, of which $ 1.4 million was incurred as of December 31, 2019. Upon the completion of the IPO, all shares of Series A, B, and C redeemable convertible preferred stock then outstanding were converted into 31,968,570 shares of common stock on a one-to-one basis. In addition, on the completion of the IPO, all the Company’s outstanding preferred stock warrants were converted into warrants to purchase an aggregate of 256,588 shares of common stock, which resulted in the reclassification of the convertible preferred stock warrant liability to additional paid-in capital. In connection with the Company’s IPO, in May 2020, the Company’s certificate of incorporation was amended and restated to provide for 300,000,000 authorized shares of common stock with a par value of $ 0.001 per share and 10,000,000 authorized shares of preferred stock with a par value of $ 0.001 per share.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies COVID-19 and CARES Act The global healthcare system continues to face an unprecedented challenge as a result of the novel coronavirus, or COVID-19, situation and its impact. COVID-19 is having, and may continue to have, an adverse impact on significant aspects of the Company and the business, including the demand for products, business operations, and the ability to research and develop and bring to market new products and services. The business was most acutely affected by a decline in procedural volumes during the first half of 2020, and the results of 2021 reflect some recovery from these declines the Company experienced in 2020 as a result of COVID-19. However, with cases continuing to resurge in certain areas, and hospitals at capacity in some instances due to non-COVID-19 treatments, to the extent individuals and hospital systems de-prioritize, delay or cancel deferrable medical procedures, the Company’s business, cash flows, financial condition and results of operations may continue to be negatively affected. In response to the impact of COVID-19, the Company implemented a variety of measures to help manage through the impact and position it to resume operations quickly and efficiently once these restrictions were lifted. The Company continues to focus its efforts on the health and safety of patients, healthcare providers and employees, while executing its mission of transforming lives of venous thromboembolism (“VTE”) patients. However, the Company expects the COVID-19 pandemic may continue to negatively impact our future performance. The Taxpayer Certainty and Disaster Tax Relief Act of 2020 ("the Act"), was enacted on December 27, 2020. It was a response to continued market volatility and instability resulting from COVID-19 and includes provisions to support businesses in the form of loans, grants, and tax changes, among other types of relief. The Company has reviewed and incorporated the income tax changes included in the Act, including the deductibility of meals expenses previously not deductible for tax purposes. The Company does not believe there will be a material effect on the Company’s income tax provision. The Company has not and currently does not expect to apply for loans or grants expanded by the Act. Basis of Preparation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). Principles of Consolidation The accompanying consolidated financial statements include the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Management Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements may include, but are not limited to, collectability of receivables, recoverability of long-lived assets, valuation of inventory, fair value of common stock warrants, fair value of preferred stock warrant liabilities, fair value of stock options, recoverability of net deferred tax assets and related valuation allowance, and certain accruals. Estimates are based on historical experience and on various assumptions that the Company believes are reasonable under current circumstances. Actual results could differ materially from those estimates. Management periodically evaluates such estimates and assumptions, and they are adjusted prospectively based upon such periodic evaluation. JOBS Act Accounting Election The JOBS Act allows an emerging growth company to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. Effective December 31, 2021, the Company was no longer an “emerging growth company” within the meaning of the JOBS Act and can no longer take advantage of this extended transition period. Prior to December 31, 2021, the Company had elected to use this extended transition period and, as a result, our financial statements may not have been comparable to companies that comply with public company effective dates. Cash, Cash Equivalents and Restricted Cash The Company considers cash on hand, cash in demand deposit accounts including money market funds, and instruments with a maturity date of 90 days or less at date of purchase to be cash and cash equivalents. The Company maintains its cash, cash equivalent and restricted cash balances with banks. At times, the cash and cash equivalent balances may exceed federally insured limits. The Company does not believe that this results in any significant credit risk as the Company’s policy is to place its cash and cash equivalents in highly-rated financial institutions. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): December 31, 2021 2020 Cash and cash equivalents $ 92,752 $ 114,229 Restricted cash — 388 Total cash, cash equivalent and restricted cash $ 92,752 $ 114,617 Restricted cash as of December 31, 2020 consisted of a cash secured letter of credit in the amount of $ 338,000 representing collateral for the Company’s facility lease and a compensating balance of $ 50,000 to secure the Company’s corporate purchasing cards. In February 2021, the Company cancelled both the cash secured letter of credit and corporate purchasing card program and moved them both to its current bank, with no required cash security. Accordingly, as of December 31, 2021, the Company had no restricted cash. Investments Investments in debt securities have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. The Company determines the appropriate classification of its investments in available-for-sale debt securities at the time of purchase. Available-for-sale securities with original maturities less than 12 months at the date of purchase are considered short-term investments. Available-for-sale debt securities with maturities greater than 12 months from the balance sheet date are classified as long-term investments on the consolidated balance sheets. Unrealized gains and losses are excluded from earnings and reported as a component of comprehensive income (loss). The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company’s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on marketable securities are included in other income (expenses), net on the consolidated statements of operations. The cost of investments sold is based on the specific-identification method. Interest on marketable securities is included in interest income. Accounts Receivable, net Trade accounts receivable are recorded at the invoiced amount, net of any allowance for credit losses. The Company evaluates the expected credit losses of accounts receivable, considering historical credit losses, current customer-specific information and other relevant factors when determining the allowance. An increase to the allowance for credit losses results in a corresponding increase in selling, general and administrative ("SG&A") expenses. The Company charges off uncollectible receivables against the allowance when all attempts to collect the receivable have failed. The allowance for credit losses was $ 40,000 and $ 62,000 as of December 31, 2021 and 2020, respectively. Despite the Company’s efforts to minimize credit risk exposure, customers could be adversely affected if future economic and industry trends, including those related to COVID-19, change in such a manner as to negatively impact their cash flows. The full effects of COVID-19 on the Company’s customers are highly uncertain and cannot be predicted. As a result, the Company’s future collection experience can differ significantly from historical collection trends. If the Company’s clients experience a negative impact on their cash flows, it could have a material adverse effect on the Company’s results of operations and financial condition. Upon adoption of Accounting Standard Update (“ASU”) 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments , the Company did not recognize any adjustment to the beginning balance of retained earnings as of January 1, 2021, as the impact from the adoption was not material. Inventories, net The Company values inventory at the lower of the actual cost to purchase or manufacture the inventory or net realizable value for such inventory. Cost, which includes material, labor and overhead costs, is determined on the first-in, first out method, or FIFO. The Company regularly reviews inventory quantities in process and on hand, and when appropriate, records a provision for obsolete and excess inventory. The Company writes down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements based on future demand and as compared to remaining shelf life. The estimate of excess quantities is subjective and primarily dependent on the Company’s estimates of future demand for a particular product. If the estimate of future demand is inaccurate based on actual sales, the Company may increase the write down for excess inventory for that component and record a charge to inventory impairment in the accompanying consolidated statement of operations and comprehensive income (loss). Property and Equipment, net Property and equipment are stated at cost. Additions and improvements that extend the lives of the assets are capitalized while expenditures for repairs and maintenance are expensed as incurred. Depreciation is provided using the straight-line method over the estimated useful lives of the assets, ranging from three to seven years . Leasehold improvements are depreciated over the shorter of the useful life of the improvement or the lease term , including renewal periods that are reasonably assured. Upon sale or disposition of property and equipment, any gain or loss is included as other income (expense) in the accompanying consolidated statement of operations and comprehensive income (loss). Right-of-use Assets and Lease Liabilities The Company determines if an arrangement contains a lease at inception and determines the classification of the lease, as either operating or finance, at commencement. After the adoption of the new lease standard on January 1, 2021, right-of-use assets and lease liabilities are recorded based on the present value of future lease payments which factors in certain qualifying initial direct costs incurred as well as any lease incentives received. If an implicit rate is not readily determinable, the Company utilizes inputs from third-party lenders to determine the appropriate discount rate. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term. Lease terms may factor in options to extend or terminate the lease. The Company adheres to the short-term lease recognition exemption for all classes of assets (i.e. facilities and equipment). As a result, leases with an initial term of twelve months or less are not recorded on the balance sheet and are recognized on a straight-line basis over the lease term. In addition, for certain equipment leases, the Company accounts for lease and non-lease components, such as services, as a single lease component as permitted. Public Offering Costs Costs related to public offerings, which consist of direct incremental legal, printing and accounting fees are deferred until the offering is completed. Upon completion of the offering, these costs are offset against the offering proceeds within the consolidated statements of stockholders' equity. Impairment of Long-lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. The Company has not identified any such impairment losses to date. Fair Value of Financial Instruments The Company’s cash, cash equivalents and restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their liquidity or short maturities. The Company measures and records certain financial assets and liabilities at fair value on a recurring basis. U.S. GAAP provides a fair value hierarchy that distinguishes between (i) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (ii) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels. • Level 1—Adjusted quoted prices in active markets for identical assets or liabilities. • Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets or liabilities. See Note 3 for further information. Convertible Preferred Stock Warrant Liability The Company accounted for its freestanding warrants to purchase shares of the Company’s convertible preferred stock as liabilities at fair value upon issuance primarily because the preferred shares underlying the warrants contained contingent redemption features outside the control of the Company. The warrants were subject to remeasurement at each balance sheet date and any change in fair value was included as a component of other income (expense) in the condensed consolidated statements of operations and comprehensive income (loss). The carrying value of the warrants continued to be adjusted until the completion of the IPO, which occurred in May 2020. At that time, the preferred stock warrants were converted to common stock warrants and the related liability was adjusted to fair value and reclassified to additional paid-in capital, a component of stockholders’ equity. Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company sells its products primarily to hospitals in the United States utilizing the Company’s direct sales force. The Company recognizes revenue for arrangements where the Company has satisfied its performance obligation of shipping or delivering the product. For sales where the Company’s sales representative hand-deliver products directly to the hospitals, control of the products transfers to the customers upon such hand delivery. For sales where products are shipped, control of the products transfers either upon shipment or delivery of the products to the customer, depending on the shipping terms and conditions. Revenue from product sales is comprised of product revenue, net of product returns, administrative fees and sales rebates. Performance Obligation —The Company has revenue arrangements that consist of a single performance obligation, the shipping or delivery of the Company’s products. The satisfaction of this performance obligation occurs with the transfer of control of the Company’s product to its customers, either upon shipment or delivery of the product. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of revenue recognized is based on the transaction price, which represents the invoiced amount, net of administrative fees and sales rebates, where applicable. The Company provides a standard 30-day unconditional right of return period. The Company establishes estimated provisions for returns at the time of sale based on historical experience. Historically, the actual product returns have been immaterial to the Company’s consolidated financial statements. As of December 31, 2021 and 2020, the Company recorded $ 448,000 and $ 498,000 , respectively, of unbilled receivables, which are included in accounts receivable, net, in the accompanying consolidated balance sheets. Revenue for ClotTriever and FlowTriever products as a percentage of total revenue was derived as follow: Years Ended December 31, 2021 2020 2019 ClotTriever 32 % 37 % 38 % FlowTriever 68 % 63 % 62 % The Company offers payment terms to its customers of less than three months and these terms do not include a significant financing component. The Company excludes taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price. The Company offers its standard warranty to all customers. The Company does not sell any warranties on a standalone basis. The Company’s warranty provides that its products are free of material defects and conform to specifications, and includes an offer to repair, replace or refund the purchase price of defective products. This assurance does not constitute a service and is not considered a separate performance obligation. The Company estimates warranty liabilities at the time of revenue recognition and records it as a charge to cost of goods sold. The warranty liability as of December 31, 2021 and 2020 and warranty cost recognized for the years ended December 31, 2021, 2020 and 2019 were not significant. Costs associated with product sales including commissions are recorded in SG&A expenses. The Company applies the practical expedient and recognizes commissions as expense when incurred because the amortization period is less than one year. Cost of Goods Sold Cost of goods sold consists primarily of the cost of raw materials, components, direct labor and manufacturing overhead. Overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management, including stock-based compensation. Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalty expense. Advertising Costs Advertising costs are charged to operations as incurred. Advertising costs were $ 269,000 , $ 333,000 and $ 90,000 for the years ended December 31, 2021, 2020 and 2019 , respectively. Advertising costs are included in SG&A expenses in the accompanying consolidated statements of operations and comprehensive income (loss). Research and Development Research and development costs are expensed as incurred and include the costs to design, develop, test, deploy and enhance new and existing products. Research and development costs also include expenses associated with the purchase of intellectual property relating to a particular research and development project that has no alternative future uses, clinical studies, registries and sponsored researches. These costs include direct salary and employee benefit related costs for research and development personnel, costs for materials used and costs for outside services. Patent-related Expenditures Expenditures related to patent research and applications, which are primarily legal fees, are expensed as incurred and are included in SG&A expenses in the accompanying consolidated statements of operations and comprehensive income (loss). Stock-based Compensation The Company’s employee and non-employee share-based awards result in a cost that is measured at fair value on the awards’ grant date, based on the estimated number of awards that are expected to vest. Stock-based compensation is recognized over the service period. Income Taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Management assesses the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. As of December 31, 2021 and 2020, the net deferred tax assets have been fully offset by a valuation allowance. The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected in the period in which judgment occurs. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of provision for income taxes. Foreign Currency Translation When the functional currencies of the Company’s foreign subsidiaries are currencies other than the U.S. dollar, the assets and liabilities of the foreign subsidiaries are translated into U.S. dollars at the exchange rate in effect on the balance sheet date. Income and expense items of the subsidiaries are translated into U.S. dollars at the average exchange rates prevailing during the period. Gains or losses from these translation adjustments are reported as a separate component of stockholders’ equity in accumulated other comprehensive income (loss) until there is a sale, or complete or substantially complete liquidation of the Company’s investment in the foreign subsidiaries, at which time the gains or losses will be realized and included in net income (loss). Transaction gains and losses are included in other income (expense) and have not been significant for the periods presented. The Company’s intercompany accounts are denominated in the functional currencies of the foreign subsidiaries. Gains and losses resulting from the remeasurement of intercompany transactions that the Company considers to be of a long-term investment nature are recorded in accumulated other comprehensive income or loss as a separate component of stockholders’ equity, while gains and losses resulting from the remeasurement of intercompany transactions from those foreign subsidiaries for which the Company anticipates settlement in the foreseeable future are recorded in the consolidated statement of operations. Comprehensive Income (Loss) The Company’s comprehensive income (loss) is comprised of net income (loss) and changes in unrealized gain and losses on available-for-sale investments and gains or losses from foreign currency translation adjustments. Net Income (Loss) per Share of Common Stock Basic net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net income (loss) per share calculation, redeemable convertible preferred stock and warrants, and common stock options are potentially dilutive securities. For the years the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive. The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. The shares of the Company’s convertible preferred stock participate in any dividends declared by the Company and are therefore considered to be participating securities. Segment Reporting Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company has determined it operates in one segment - the development and commercialization of innovative and minimally invasive mechanical thrombectomy devices to treat thromboembolism in the venous system. Geographically, the Company sells primarily to hospitals in the United States. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. Recently Adopted Accounting Pronouncements In February 2017, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASC 842”), as amended, which requires lessees to recognize “right of use” assets and liabilities for all leases with terms of more than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASC842 requires additional quantitative and qualitative financial statement note disclosures about the leases, significant judgments made in accounting for those leases and amounts recognized in the financial statements about those leases. The Company adopted the requirement of ASC 842 effective January 1, 2021 and elected the modified retrospective method for all lease arrangements with a cumulative-effect adjustment as of January 1, 2021. Results for reporting periods beginning on or after January 1, 2021 are presented under ASC 842, while prior period amounts were not adjusted and are reported in accordance with the Company’s historic accounting under ASC 840, Leases. For leases that commenced before the effective date of ASC 842, the Company elected the transition package of three practical expedients permitted within ASC 842, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. The Company also elected the hindsight practical expedient, which permits the use of hindsight when determining lease term and impairment of right-of-use assets. Further, the Company elected a short-term lease exception policy, permitting the Company to not apply the recognition requirements of this standard to short-term leases (i.e., leases with terms of 12 months or less) and an accounting policy to account for lease and non-lease components as a single component for certain classes of assets. The Company determines if an arrangement is a lease at inception. As a lessee, right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company does not have any outstanding debt or committed credit facilities, the Company estimates the incremental borrowing rate based on prevailing financial market conditions, and management judgment. Operating lease right-of-use assets also include any lease payments made at or before lease commencement and exclude any lease incentives received. The lease terms used to calculate the right-of-use asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense, while the expense for finance leases is recognized as amortization expense and interest expense using the accelerated interest method of recognition. As a result of adopting ASC 842 as of January 1, 2021, the Company recorded an operating lease right-of-use asset of approximately $ 1.2 million and related operating lease liability of approximately $ 1.3 million based on the present value of the future lease payments on the date of adoption. There was no cumulative-effect adjustment recorded to retained earnings upon adoption. Adopting ASC 842 did not have a material impact on the Company’s condensed consolidated statements of operations and cash flows. See Note 7, Commitments and Contingencies, for further discussion of the Company’s adoption of ASC 842 and related disclosures. In December 2019, the FASB issued ASU 2019-12, Income Taxes – Simplifying the Accounting for Income Taxes , which simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step-up in the tax basis of goodwill and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. ASU 2019-12 is effective for annual periods beginning after December 15, 2020, including interim periods within those fiscal years, and early adoption is permitted. The Company adopted this guidance effective January 1, 2021 and the adoption of this standard did not have a material impact on its consolidated financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting , which expands guidance on accounting for share-based payment awards, which includes share-based payment transactions for acquiring goods and services from nonemployees and aligns the accounting for share-based payments for employees and non-employees. The Company adopted this guidance effective January 1, 2020. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments , which changes the impairment model for most financial assets. The new model uses a forward-looking expected loss method, which will generally result in earlier recognition of allowances for losses. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. This st

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of December 31, 2021 and 2020 (in thousands): December 31, 2021 Level 1 Level 2 Level 3 Aggregate Fair Value Financial Assets Cash and cash equivalents: Money market mutual funds $ 48,595 $ — $ — $ 48,595 Total included in cash and cash equivalents 48,595 — — 48,595 Investments: U.S. Treasury securities 44,322 — — 44,322 Corporate debt securities and commercial paper — 39,026 — 39,026 Total included in short-term investments 44,322 39,026 — 83,348 U.S. Treasury securities included in long-term investments 3,983 — — 3,983 Total assets $ 96,900 $ 39,026 $ — $ 135,926 December 31, 2020 Level 1 Level 2 Level 3 Aggregate Fair Value Financial Assets Cash and cash equivalents: Money market mutual funds $ 1,034 $ — $ — $ 1,034 U.S. Treasury securities 33,996 — — 33,996 Total included in cash and cash equivalents 35,030 — — 35,030 Investments: U.S. Treasury securities 24,992 — — 24,992 U.S. Government agencies — 24,989 — 24,989 Total included in short-term investments 24,992 24,989 — 49,981 Total assets $ 60,022 $ 24,989 $ — $ 85,011 There were no transfers between Levels 1, 2 or 3 for the periods presented. There were no warrants outstanding as of December 31, 2021. The change in the fair value of the warrant liability is summarized below (in thousands): Years Ended December 31, 2020 2019 Beginning balance $ 1,169 $ 212 Change in fair value of warrant liability 3,317 957 Conversion of preferred stock warrants to common ( 4,486 ) — Ending balance $ — $ 1,169 The valuation of the Company’s convertible preferred stock warrant liability contains unobservable inputs that reflect the Company’s own assumptions for which there was little, if any, market activity for at the measurement date. Accordingly, the Company’s convertible preferred stock warrant liability was measured at fair value in a recurring basis using unobservable inputs and are classified as Level 3 inputs, and any change in fair value was recognized as other expense in the consolidated statements of operations (see Note 11).

Cash Equivalents and Short-Term

Cash Equivalents and Short-Term Investments	12 Months Ended
	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Cash Equivalents and Short-Term Investments	4. Cash Equivalents and Investments The following is a summary of the Company’s cash equivalents and investments as of December 31, 2021 and 2020 (in thousands): December 31, 2021 Amortized Cost Basis Unrealized Gain Unrealized Loss Fair Value Financial Assets Cash and cash equivalents: Money market mutual funds $ 48,595 $ — $ — $ 48,595 Total included in cash and cash equivalents 48,595 — — 48,595 Investments: U.S. Treasury securities 44,349 — ( 27 ) 44,322 Corporate debt securities and commercial paper 39,012 14 — 39,026 Total included in short-term investments 83,361 14 ( 27 ) 83,348 U.S. Treasury securities included in long-term investments 3,993 — ( 10 ) 3,983 Total assets $ 135,949 $ 14 $ ( 37 ) $ 135,926 December 31, 2020 Amortized Cost Basis Unrealized Gain Unrealized Loss Fair Value Financial Assets Cash and cash equivalents: Money market mutual funds $ 1,034 $ — $ — $ 1,034 U.S. Treasury securities 33,996 — — 33,996 Total included in cash and cash equivalents 35,030 — — 35,030 Investments: U.S. Treasury securities 24,991 1 — 24,992 U.S. Government agencies 24,986 3 — 24,989 Total included in short-term investments 49,977 4 — 49,981 Total assets $ 85,007 $ 4 $ — $ 85,011 The Company regularly reviews the changes to the rating of its debt securities and reasonably monitors the surrounding economic conditions to assess the risk of expected credit losses. As of December 31, 2021 , the risk of expected credit losses was not significant.

Inventories, Net

Inventories, Net	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventories, Net	5. Inventories, net Inventories are net of reserves totaling $ 285,000 and $ 264,000 as of December 31, 2021 and 2020, respectively, and consist of the following (in thousands): December 31, 2021 2020 Raw materials $ 5,763 $ 2,607 Work-in-process 1,490 787 Finished goods 13,800 7,203 $ 21,053 $ 10,597

Property and Equipment. net

Property and Equipment. net	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment. net	6. Property and Equipment. net Property and equipment consist of the following (in thousands): December 31, 2021 2020 Manufacturing equipment $ 7,408 $ 4,003 Leasehold improvements 4,712 1,737 Computer software 100 128 Furniture and fixtures 3,044 363 Computer hardware 2,864 980 Assets in progress 3,124 2,320 21,252 9,531 Accumulated depreciation ( 4,781 ) ( 2,033 ) $ 16,471 $ 7,498 Depreciation expense of $ 2,367,000 , $ 1,039,000 and $ 511,000 was included in SG&A expenses and $ 667,000 , $ 346,000 and $ 103,000 was included in cost of goods sold for the years ended December 31, 2021, 2020 and 2019, respectively. In connection with the adoption of ASC 842, the Company reclassified $ 1,556,000 of tenant improvement costs related to the Oak Canyon lease that were deemed to be lessor's assets, which were included in assets in progress as of December 31, 2020, to operating lease right-of-use assets (see Note 7). Capitalized Implementation Costs of a Hosting Arrangement The Company has software systems that are cloud-based hosting arrangements with service contracts. The Company accounts for costs incurred in connection with the implementation of these various software systems under ASU 2018-15, Intangibles—Goodwill and Other-Internal Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract . The Company expenses all costs (internal and external) that are incurred in the planning and post-implementation operation stages. As of December 31, 2021, the Company has capitalized approximately $ 785,000 in implementation costs related to the application development stage. The capitalized costs are amortized on a straight-line basis over the non-cancelable contract terms, generally three years . As of December 31, 2021 and 2020, approximately $ 391,000 and $ 228,000 , respectively, of the capitalized costs were included in prepaid expenses and other current assets and $ 55,000 and $ 0 , respectively, were included in deposits and other assets. The Company starts amortizing capitalized implementation costs when the systems are placed in production and ready for their intended use. For the years ended December 31, 2021, 2020 and 2019, amortization expense, which was included in SG&A expenses, was $ 222,000 , $ 100,000 and $ 16,000 , respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Operating Leases The Company has operating leases for facilities and certain equipment. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. Lease expense for operating leases is recognized on a straight-line basis over the lease term. For lease agreements, other than long-term real estate leases, entered into or reassessed after the adoption of ASC 842 on January 1, 2021, the Company combines lease and non-lease components. (See Note 2) In March 2019, the Company executed a five-year lease for a facility in Irvine, California, where substantially all operations of the Company have been located since September 2019. The lease expires in September 2024 and contains two optional extension periods of five years each. In addition to the minimum future lease commitments presented below, the lease requires the Company to pay property taxes, insurance, maintenance, and repair costs, which are considered variable lease payments and are not included in the lease liability. The lease includes a one-month rent holiday concession and escalation clauses for increased rent over the lease term. Concurrent with the execution of a new ten-year lease (see below), the Company entered into a termination agreement (as amended) that releases the Company from the current facility lease obligation 12 months following the commencement date of the new lease, with options to extend the lease term for up to three periods of an additional 30 days each. As of December 31, 2021, the operating lease right-of-use asset and liability were $ 367,000 and $ 413,000 , respectively, with the remaining lease term of 7 months. In October 2020, the Company entered into a ten-year lease for a facility located in Irvine, California (the “Oak Canyon lease”) with two option extension periods of five years each, which the Company has determined that it's reasonably certain to exercise. The Oak Canyon lease requires the Company to make variable lease payments , which are not included in the lease liability due to the amounts not being fixed, for property taxes, insurance, maintenance, repair costs, and certain improvements deemed to be the lessor's assets. The Oak Canyon lease includes scheduled payment escalation clauses over the lease term. The Oak Canyon lease also requires the Company to maintain a letter of credit for the benefit of the landlord in the amount of $ 1.5 million, which is secured by the Company’s Credit Agreement. The Company has moved in and taken control of the facility and has determined the lease commencement date to be September 30, 2021. On the commencement date, the Company recorded approximately $ 42.2 million of right-of-use assets and $ 28.6 million of lease liability. The right-of use-asset includes approximately $ 13.5 million, net of $ 3.7 million tenant allowance, related to prepaid lease payments for the lessor’s owned leasehold improvements which were reclassified from assets in progress and deposits and other assets. The operating lease right-of-use assets also include $ 2.8 million of additional prepaid lease payments for the lessor's owned leasehold improvements paid subsequent to the commencement date. As of December 31, 2021, the operating lease right-of-use assets and lease liabilities were $ 44.4 million and $ 28.7 million , respectively, with the weighted average remaining lease term of 235 months. The Company also leases two additional warehouse spaces located in Lake Forest and Irvine, California. As of December 31, 2021, the operating lease right-of-use assets and liabilities were $ 33,000 and $ 34,000 , respectively, with the weighted average remaining lease term of 6 months. The Company also leases certain equipment for warehouse and office use. As of December 31, 2021, the operating lease right-of-use assets and liabilities were $ 106,000 and $ 107,000 , respectively, with the weighted average remaining lease term of 42 months. As of December 31, 2021, the weighted average incremental borrowing rate used to measure operating lease liabilities was 6.0 % . During the year ended December 31, 2021, cash paid for amounts included in the measurement of operating lease liabilities was $ 14.6 million , $ 13.8 million of which related to Oak Canyon lease. Total lease cost for the year ended December 31, 2021 are as follows (in thousands): Year Ended Operating lease cost $ 1,568 Short-term lease cost 200 Variable lease cost 473 Total lease costs $ 2,241 Future minimum lease payments under operating leases liabilities as of December 31, 2021 are as follows (in thousands): Year ending December 31: Amount 2022 $ 2,542 2023 2,163 2024 2,234 2025 2,295 2026 2,361 Thereafter 39,536 Total lease payments 51,131 Less imputed interest ( 21,925 ) Total lease liabilities 29,206 Less: lease liabilities - current portion ( 802 ) Lease liabilities - noncurrent portion $ 28,404 Indemnification In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and may provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not been subject to any claims or required to defend any action related to its indemnification obligations. The Company’s amended and restated certificate of incorporation contains provisions limiting the liability of directors, and its amended and restated bylaws provide that the Company will indemnify each of its directors to the fullest extent permitted under Delaware law. The Company’s amended and restated certificate of incorporation and amended and restated bylaws also provide its board of directors with discretion to indemnify its officers and employees when determined appropriate by the board. In addition, the Company has entered and expects to continue to enter into agreements to indemnify its directors and executive officers. Legal Proceedings From time to time, the Company may become involved in legal proceedings arising out of the ordinary course of its business. Management is currently not aware of any matters that will have a material adverse effect on the consolidated financial position, results of operations or cash flows of the Company. Licensed Technology In December 2021, the Company entered into an exclusive, perpetual, royalty free, technology license agreement (the “Licensed Technology”) for use in a particular research and development project that requires total payments of approximately $ 4.2 million payable in three installments due in 2022 and 2023. The Company accounted for the purchase as a research and development expense as it was determined to have no future alternative uses. As of December 31, 2021, the Company accrued $ 4.2 million on its consolidated balance sheet, $ 2.8 million of which was included in accrued expenses and other current liabilities, and the remaining $ 1.4 million was included in other long-term liability.

Concentrations

Concentrations	12 Months Ended
	Dec. 31, 2021
Risks and Uncertainties [Abstract]
Concentrations	8. Concentrations The Company’s revenue is derived primarily from the sale of catheter-based therapeutic devices in the United States. For the years ended December 31, 2021, 2020 and 2019 , there were no customers which accounted for more than 10 % of the Company’s revenue. There were no customers which accounted for more than 10 % of the Company’s accounts receivable as of December 31, 2021 and 2020. No vendor accounted for more than 10 % of the Company’s purchases for the years ended December 31, 2021, 2020 and 2019 . There were no vendors which accounted for more than 10 % of the Company’s accounts payable as of December 31, 2021 and 2020 .

Related Party

Related Party	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party	9. Related Party Licensed Patents Certain stockholders of the Company were stockholders of Inceptus Medical, Inc. (“Inceptus”). Beginning in September 2011, the Company engaged Inceptus to develop the technology that has led to certain components used in the Company’s products, the FlowTriever and the ClotTriever systems. In October 2014, the Company, through a license agreement with Inceptus, obtained an exclusive, perpetual, fully paid-up irrevocable, worldwide license to the patents, patent applications and technology, including the right to grant and authorize sublicenses, to make, have made, use, sell, offer for sale, import and otherwise exploit products in connection with the licensed technology. The licensed technology is any and all technology involving a high wire count braid, excluding the tubular braiding subject to the sublicense agreement described below. Since the completion of the Company's IPO, Inceptus was no longer considered a related party as its stockholders were no longer principal stockholders of the Company. Sublicense Agreement In August 2019, the Company entered into a sublicense agreement with Inceptus, pursuant to which Inceptus granted to the Company a non-transferable, worldwide, exclusive sublicense to its licensed intellectual property rights related to the tubular braiding for the non-surgical removal of clots and treatment of embolism and thrombosis in human vasculature other than carotid arteries, coronary vasculature and cerebral vasculature; such rights were originally granted to Inceptus pursuant to an intellectual property license agreement with Drexel University, or Drexel License, under which Drexel retained certain rights to use, and to permit other non-commercial entities to use, the sublicensed intellectual property for educational and non-commercial research purposes. The Company is obligated to comply with, and to avoid acts or omissions that would reasonably be likely to cause a breach of the Drexel License. The sublicense agreement will continue until the expiration of the sublicensed patent, unless terminated earlier pursuant to the terms of the agreement. The Company may terminate the sublicense agreement at any time by providing prior written notice. Under the sublicense agreement, the Company is required to pay an ongoing quarterly administration fee, which amounted to $ 116,000 and $ 95,000 for the years ended December 31, 2021 and 2020, respectively. D uring the year ended 2019 the Company paid Inceptus $ 139,000 for the reimbursement of expenses and milestone and administration fees. Additionally, the Company is obligated to pay Inceptus an ongoing royalty ranging from 1 % to 1.5 % of the net sales of products utilizing the licensed intellectual property, subject to a minimum royalty quarterly fee of $ 1,000 . The Company recorded royalty expense of $ 769,000 , $ 488,000 , and $ 103,000 for the years ended December 31, 2021, 2020, and 2019, respectively. Other Services The Company utilizes MRI The Hoffman Group (“MRI”), a recruiting services company owned by the brother of the Chief Executive Officer and President and member of the board of directors of the Company. The Company paid for recruiting services provided by MRI amounting to $ 369,000 , $ 427,000 , and $ 380,000 for the years ended December 31, 2021, 2020, and 2019, respectively, which was included in operating expenses on the consolidated statements of operations. As of December 31, 2021 and 2020 , there was no balance payable to MRI.

Debt

Debt	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Debt	10. Debt Bank of America Credit Facility In September 2020, the Company entered into a senior secured revolving credit facility with Bank of America (the “Credit Agreement”), as amended, under which the Company may borrow loans up to a maximum principal amount of $ 30 million. The amount available to borrow under the Credit Agreement is comprised of a) 85 % of eligible accounts receivable, plus b) pledged cash (up to $10 million). There was no principal amount outstanding and no cash was pledged under the Credit Agreement as of December 31, 2021 and 2020. As of December 31, 2021 and 2020, the amount available to borrow under the Credit agreement was approximately $ 28.2 million and $ 28.5 million, respectively. Advances under the Credit Agreement will bear interest at a base rate per annum (the “Base Rate”) plus an applicable margin (the “Margin”). The Base Rate equals the greater of (i) the Prime Rate, (ii) the Federal funds rate plus 0.50 % , or (iii) the LIBOR rate based upon an interest period of 30 days plus 1.00 % . The Margin ranges from 1.00 % to 1.50 % based on the Company’s applicable fixed charge coverage ratio. Advances under the Credit Agreement designated as “LIBOR Loans” will bear interest at a rate per annum equal to the LIBOR rate plus the applicable Margin ranging from 2.00 % to 2.50 % based on the Company’s applicable fixed charge coverage ratio. Interest on loans outstanding under the Credit Agreement is payable monthly . Loan principal balances outstanding under the Credit Agreement are due at maturity in September 2023 . The Company may prepay any loans under the Credit Agreement at any time without any penalty or premium. The Company is also required to pay an unused line fee at an annual rate ranging from 0.25 % to 0.375 % per annum of the average daily unused portion of the aggregate revolving credit commitments under the Credit Agreement. The Credit Agreement also includes a Letter of Credit subline facility (the “LC Facility”) of up to $ 5 million. The aggregate stated amount outstanding of letter of credits reduces the total borrowing base available under the Credit Agreement. The Company is required to pay the following fees under the LC Facility are as follows: (a) a fee equal to the applicable margin in effect for LIBOR loans (currently 2.25 %) times the average daily stated amount of outstanding letter of credits; (b) a fronting fee equal to 0.125 % per annum on the stated amount of each letter of credit outstanding. As of December 31, 2021 , the Company had two letters of credit in the aggregated amount of approximately $ 1.8 million outstanding under the LC Facility. As of December 31, 2020, the Company had one letter of credit in the amount of $ 1.5 million outstanding under the LC Facility. The Company paid Bank of America a closing fee of $ 150,000 and incurred approximately $ 280,000 in legal and other fees directly related to the Credit Agreement. The Credit Agreement contains certain customary covenants and events of default, including: payment defaults, breaches of any representation, warranty or covenants, judgment defaults, cross defaults to certain other contracts, certain events with respect to governmental approvals if such events could cause a material adverse change, a material impairment in the perfection or priority of the lender's security interest or in the value of the collateral, a material adverse change in the business, operations, or condition of us or any of our subsidiaries, and a material impairment of the prospect of repayment of the loans. Upon the occurrence of an event of default, a default increase in the interest rate of an additional 2.0% could be applied to the outstanding loan balance and the lender could declare all outstanding obligations immediately due and payable and take such other actions as set forth in the loan and security agreement. The Company was in compliance with its covenant requirements as of December 31, 2021. Obligations under the Credit Agreement are secured by substantially the Company’s assets, excluding intellectual property. Signature Bank Credit Facility In December 2019, the Company entered into a $ 40 million credit facility with Signature Bank (the “SB Credit Facility”) and concurrently repaid and extinguished its term loan with East West Bank. The SB Credit Facility consisted of a term loan of up to $ 25 million and a revolving line of credit of $ 15 million. The term loan was available in two tranches: a $ 15 million tranche that was fully funded on the closing date, and a $ 10 million tranche that was available through December 2020. In March 2020, the Company borrowed an additional $ 10 million which was available under the term loan. The maturity date of the term loan was in December 2024 . Under the agreement, the Company was required to make monthly interest payments through December 2021 . The term loan bore interest at an annual rate equal to the greater of 5.50 % or the Prime Rate plus 0.50 %. Under the revolving line of credit, the Company could borrow, repay and re-borrow up to 80 % of eligible accounts receivable up to a maximum of $ 15 million. The revolving line of credit bore interest at an annual rate equal to the greater of 5.00 % or the prime rate. In August 2020, the Company repaid the SB Credit Facility in full and terminated the agreement. Deferred Financing Costs As of December 31, 2021 and 2020, costs incurred directly related to debt are presented in other assets and are being amortized over the three-year life of the Credit Agreement on the straight-line basis as follows (in thousands): December 31, 2021 2020 Deferred financing costs $ 430 $ 430 Accumulated amortization ( 191 ) ( 47 ) Unamortized deferred financing costs $ 239 $ 383

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Stockholders' Equity	11. Stockholders’ Equity Redeemable Convertible Preferred Stock In connection with the IPO in May 2020, the 31,968,570 shares of redeemable convertible preferred stock then outstanding were converted into 31,968,570 shares of common stock. Accumulated Other Comprehensive Income (Loss) The following table summarizes the changes in accumulated balances of other comprehensive income (loss), net of tax, for the years ended December 31, 2021 and 2020 (in thousands): Unrealized Gain (Loss) om Investments Foreign Currency Translation Accumulated Other Comprehensive Income (Loss) Balance, January 1, 2020 $ — $ — $ — Other comprehensive income 4 — 4 Balance, December 31, 2020 4 — 4 Other comprehensive loss ( 27 ) ( 379 ) ( 406 ) Balance, December 31, 2021 $ ( 23 ) $ ( 379 ) $ ( 402 ) Warrants There were no warrants outstanding as of December 31, 2021 and 2020 . The Company had previously issued common stock warrants and redeemable convertible preferred stock warrants (“Preferred Warrants”) allowing the holders to obtain shares of redeemable convertible preferred stock that contain a liquidation preference. Because this liquidation preference may have been payable in cash upon a change in control of the Company or upon exercise of redemption rights and because such a transaction was considered to be outside of the control of the Company, the Preferred Warrants were classified as liabilities in the Company’s consolidated balance sheets and were presented at their estimated fair values at each reporting date. On the completion of the IPO, all the outstanding Preferred Warrants were converted into warrants to purchase an aggregate of 256,588 shares of common stock, which resulted in the reclassification of the convertible preferred stock warrant liabilities to additional paid-in capital. In June 2020, 27,810 common stock warrants were exercised for cash. In addition, 77,030 warrants were net exercised and the Company issued 74,723 shares of common stock. In November 2020, the remaining 179,558 warrants were net exercised and the Company issued 174,776 shares of common stock. The fair value of the Preferred Warrants was determined using the Black Scholes option pricing model with the following assumptions: May 21, 2020 (1) December 31, 2019 Series A Series B Series A Series B Expected volatility 51.10 % 50.00 % 41.40 % 39.80 % Preferred stock fair value (per share) $ 19.00 $ 19.00 $ 5.88 $ 5.94 Dividend yield 0.00 % 0.00 % 0.00 % 0.00 % Risk free interest rates 0.17 % 0.53 % 1.58 % 1.83 % Expected remaining term in years 1.55 5.94 - 6.86 1.95 6.33 - 7.25 (1) Date the Company's registration statement on Form S-1 was declared effective.

Equity Incentive Plans

Equity Incentive Plans	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Equity Incentive Plans	. Equity Incentive Plans In 2011, the Company adopted the 2011 Equity Incentive Plan (the “2011 Plan”) to permit the grant of share-based awards, such as stock grants and incentives and non-qualified stock options to employees, directors, consultants and advisors. The Board has the authority to determine to whom awards will be granted, the number of shares, the term and the exercise price. In March 2020, the Company adopted the 2020 Incentive Award Plan (the “2020 Plan”), which became effective in connection with the IPO. As a result, the Company may not grant any additional awards under the 2011 Plan. The 2011 Plan will continue to govern outstanding equity awards granted thereunder. The Company initially reserved 3,468,048 shares of common stock for the issuance of a variety of awards under the 2020 Plan, including stock options, stock appreciation rights, awards of restricted stock and awards of restricted stock units. In addition, the number of shares of common stock reserved for issuance under the 2020 Plan will automatically increase on the first day of January for a period of up to ten years , commencing on January 1, 2021, in an amount equal to 3 % of the total number of shares of the Company’s capital stock outstanding on the last day of the preceding year, or a lesser number of shares determined by the Company’s board of directors. As of December 31, 2021, there were 4,670,472 shares available for issuance under the 2020 Plan, including 1,477,548 additional shares reserved effective January 1, 2021. 2011 Equity Incentive Plan Stock Options A summary of stock option activity under the 2011 Plan for the years ended December 31, 2021 is as follows (intrinsic value in thousands): Number of Weighted Weighted Weighted Intrinsic Outstanding , December 31, 2018 2,688,527 $ 0.39 $ 0.31 8.95 $ 190 Granted 1,901,837 1.48 1.19 Exercised ( 409,893 ) 0.31 0.26 560 Cancelled ( 98,169 ) 0.40 0.34 Outstanding , December 31, 2019 4,082,302 0.90 0.74 8.76 22,667 Granted 305,494 7.47 3.73 Exercised ( 851,190 ) 0.55 0.50 49,413 Cancelled ( 99,821 ) 8.39 3.62 Outstanding , December 31, 2020 3,436,785 1.36 0.98 8.05 295,331 Exercised ( 806,008 ) 1.08 0.83 73,299 Cancelled ( 56,423 ) 2.17 1.36 Outstanding , December 31, 2021 2,574,354 $ 1.43 $ 1.02 7.07 $ 231,286 Vested and exercisable at December 31, 2021 1,598,546 $ 1.06 $ 0.78 6.88 $ 144,203 Vested and expected to vest at December 31, 2021 2,526,814 $ 1.40 $ 1.00 7.06 $ 227,074 The aggregate intrinsic values of options outstanding, vested and exercisable, and vested and expected to vest were calculated as the difference between the exercise price of the options and the estimated fair value of the Company’s common stock. The fair value of each option grant under the 2011 Plan was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: Years Ended December 31, 2020 2019 Expected volatility 40.60 % 53.5 % - 93.4 % Weighted-average volatility 40.60 % 83.24 % Common stock fair value (per share) $ 7.88 - $ 9.05 $ 0.59 -$ 6.15 Dividend yield 0.00 % 0.00 % Risk free interest rates 1.46 % - 1.68 % 1.67 % - 2.44 % Expected remaining term in years 5.90 - 6.07 5.02 - 7.00 Expected volatility —The expected volatility is derived from an average of the historical volatilities of the common stock of the Company and several other entities with characteristics similar to those of the Company, such as the size and operational and economic similarities to the Company's principal business operations; Common Stock fair value —The Company uses the market closing price of its Class A common stock, as reported on the NASDAQ Global Select Market, for the fair value. Prior to the IPO, the fair value of the Company’s common stock was determined by the board of directors with assistance from management. The board of directors determined the fair value of common stock by considering independent valuation reports and a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial performance, the lack of liquidity of the Company’s common stock and the general and industry-specific economic outlook. Dividend yield —The Company has no t declared or paid any dividends. Risk-free interest rates —The Company applies the risk-free interest rate based on the U.S. Treasury yield for the expected term of the option. Expected term —The Company calculated the expected term as the average of the contractual term of the option and the vesting period for its employee stock options as the Company believes this represents the best estimate of the expected terms of a new employee stock option. The Company uses its historical rate of cancelled or expired unvested shares since inception of the plan as the expected forfeiture rate. In 2021, the Company accelerated the vesting of 4,993 stock options for an employee and accounted for the vesting acceleration as a modification under ASC 718. The Company recognized additional stock-based compensation expense as a result of this modification of approximately $ 0.5 million, which was determined using the Black-Sholes option pricing model with a weighted average volatility of 51.90 %, common stock value of $ 105.54 , dividend yield of 0.00 % and risk free interest rate of 0.10 % and was included in SG&A expenses on the consolidated statements of operations. Restricted Stock Units In March 2019, the Company granted, under the 2011 Plan, 2,867,326 restricted stock unit awards (“RSUs”) to certain employees that vest only upon the satisfaction of both a time-based service condition and a performance-based condition. The performance-based condition is a liquidity event requirement that was satisfied on the effective date of the IPO of the Company’s common stock. These RSUs are subject to a four-year cliff vesting and will vest in March 2023. If the RSUs vest, the actual number of RSUs that will vest will be dependent on the per share value of the Company’s common stock, which is a market-based condition, determined based on the average closing price of the Company’s common stock for the three-month period immediately preceding the satisfaction of the service condition. In 2021, the Company accelerated the vesting of 96,658 RSUs for an employee and accounted for the vesting acceleration as a modification under ASC 718. The Company recognized a one-time stock-based compensation expense as a result of this modification of approximately $ 8.3 million, which was determined based on the fair value of the Company’s shares of common stock at the time of the modification and was included in SG&A expenses on the consolidated statements of operations. RSU activities under the 2011 Plan is set forth below (intrinsic value in thousands): Number of Weighted Outstanding, December 31, 2018 — $ — Granted 2,867,326 0.17 Outstanding, December 31, 2019 2,867,326 0.17 Outstanding, December 31, 2020 2,867,326 0.17 Vested ( 96,658 ) 0.17 Cancelled ( 57,994 ) 0.17 Outstanding, December 31, 2021 2,712,674 $ 0.17 The probabilities of the actual number of RSUs expected to vest are reflected in the grant date fair values, and the compensation expense for these awards will be recognized assuming the requisite service period is rendered, and only if the performance-based condition is considered probable to be satisfied. The estimated fair value of these RSUs were determined on the grant date using the Monte Carlo simulation model, which utilizes multiple input variables to simulate a range of our possible future equity values and estimates the probabilities of the potential payouts. The determination of the estimated grant date fair value of these RSUs is affected by our equity valuation and a number of assumptions including our future estimated enterprise value, our risk-free interest rate, expected volatility and dividend yield. The following assumptions were used to calculate the fair value of these RSUs in the Monte Carlo simulation model at the grant date: Year Ended December 31, 2019 Expected term (in years) 4.00 Expected volatility 50.00 % Dividend yield 0.00 % Risk free interest rate 2.41 % T hrough May 21, 2020, no stock-based compensation expense had been recognized for these awards because the liquidity event performance condition described above for the RSUs was not considered probable of being satisfied. Upon the completion of the Company’s IPO, the Company recognized $ 159,000 of cumulative stock-based compensation expense related to such awards, which is included in SG&A expenses for the year ended December 31, 2020. 2020 Incentive Award Plan RSUs are share awards that entitle the holder to receive freely tradable shares of the Company’s common stock upon vesting. The RSUs cannot be transferred and the awards are subject to forfeiture if the holder’s employment terminates prior to the release of the vesting restrictions. The RSUs generally vest over a four-year period with straight-line vesting and a 25 % one-year cliff or over a three-year period in equal amounts on a quarterly basis, provided the employee remains continuously employed with the Company . The fair value of the RSUs is equal to the closing price of the Company’s common stock on the grant date. RSU activity under the 2020 Plan is set forth below (intrinsic value in thousands): Number of Weighted Outstanding, December 31, 2019 — $ — Granted 227,963 58.68 Vested ( 1,199 ) 51.41 Cancelled ( 4,200 ) 51.41 Outstanding , December 31, 2020 222,564 58.86 Granted 515,880 98.98 Vested ( 99,758 ) 78.15 Cancelled ( 27,481 ) 86.41 Outstanding , December 31, 2021 611,205 $ 88.34 The total fair value of RSUs vested under both the 2011 Plan and 2020 Plan during the years ended December 31, 2021 and 2020, was $ 17.7 million and $ 80,000 , respectively. In 2021, the Company accelerated the vesting of 8,947 RSUs for a director and accounted for the vesting acceleration as a modification under ASC 718. The Company recognized a one-time stock-based compensation expense as a result of this modification of approximately $ 0.4 million, which was determined based on the fair value of the Company’s shares of common stock at the time of the modification and was included in SG&A expenses on the consolidated statements of operations. Stock-based Compensation Expense Total compensation cost for all share-based payment arrangements recognized, including $ 2,386,000 and $ 560,000 of stock-based compensation expense related to the Employee Stock Purchase Plan for the years ended December 31, 2021 and 2020, respectively, was as follows (in thousands): Years Ended December 31, 2021 2020 2019 Cost of goods sold $ 815 $ 155 $ 52 Research and development 2,214 592 99 Selling, general and administrative 22,419 2,777 354 Total share-based compensation expenses $ 25,448 $ 3,524 $ 505 Total compensation costs as of December 31, 2021 related to all non-vested awards to be recognized in future periods was $ 47,329,000 and is expected to be recognized over the remaining weighted average period of 3.1 years. The income tax benefit from the exercises of stock options before valuation allowance was $ 10.3 million, $ 4.9 million and nil for the years ended December 31, 2021, 2020 and 2019, respectively. Employee Stock Purchase Plan In May 2020, the Company adopted the 2020 Employee Stock Purchase Plan (“ESPP”), which became effective on the date the ESPP was adopted by the Company’s board of directors. The Company has initially reserved 990,870 shares of common stock for purchase under the ESPP. Each offering to the employees to purchase stock under the ESPP will begin on each August 1 and February 1 and will end on the following January 31 and July 31, respectively. The first offering period began on August 1, 2020 and ends on January 31, 2021 . On each purchase date, which falls on the last date of each offering period, ESPP participants will purchase shares of common stock at a price per share equal to 85 % of the lesser of (1) the fair market value per share of the common stock on the offering date or (2) the fair market value of the common stock on the purchase date. The occurrence and duration of offering periods under the ESPP are subject to the determinations of the Company’s Compensation Committee, in its sole discretion. The fair value of the ESPP shares is estimated using the Black-Scholes option pricing model. Years Ended December 31, 2021 2020 Expected term (in years) 0.5 0.5 Expected volatility 51.47 %- 51.91 % 49.23 % Dividend yield 0.00 % 0.00 % Risk free interest rate 0.06 %- 0.08 % 0.11 % As of December 31, 2021 , 85,049 shares of common stock have been purchased under the ESPP and 1,398,337 shares are reserved for future purchases. As of December 31, 2020, no shares of common stock had been purchased under the ESPP.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes The Company's income tax provision is summarized as follows (in thousands): Years Ended December 31, 2021 2020 2019 Income (loss) before provision for income taxes: United States $ 18,301 $ 14,541 $ ( 1,192 ) Foreign ( 7,616 ) ( 752 ) — Income (loss) before income taxes $ 10,685 $ 13,789 $ ( 1,192 ) Current tax expense: State $ 832 $ — $ — Foreign 13 — — Total current tax expense 845 — — Total provision for income taxes $ 845 $ — $ — Provision for income taxes as a percentage 7.9 % 0.0 % 0.0 % Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards. The tax effects of significant items comprising the Company’s deferred taxes are as follows: December 31, 2021 2020 Deferred tax assets Inventory $ 778 $ 97 Intangible asset basis 2,390 1,475 Accrued employee compensation 1,028 547 Net operating losses and capital 8,918 8,033 Credit carryforwards 7,750 2,379 Equity compensation 1,511 358 Operating leases 7,432 — Others 44 64 Total deferred tax assets $ 29,851 $ 12,953 Deferred tax liabilities Fixed asset basis $ ( 2,810 ) $ ( 1,069 ) Right-of-use assets ( 9,138 ) — Other liabilities ( 7 ) ( 18 ) Total deferred tax liabilities $ ( 11,955 ) $ ( 1,087 ) Valuation allowance $ ( 17,896 ) $ ( 11,866 ) Net deferred tax assets $ — $ — ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not”. Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carryforward periods. Based on its evaluation, including projected taxable losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, according has provided for a valuation allowance. The Company will continue to assess its position on the realizability of its deferred tax assets, until such time as sufficient positive evidence may become available to allow the Company to reach a conclusion that a significant portion of the valuation allowance will no longer be needed. Any release of the valuation allowance will result in a material benefit recognized in the quarter of release. T he valuation allowance increased by approximately $ 6.0 million during the year ended December 31, 2021. The effective tax rate of the Company’s provision for income taxes differs from the federal statutory rate as follows: Years Ended December 31, 2021 2020 2019 Statutory rate $ 2,244 $ 2,896 $ ( 265 ) State taxes, net of federal benefit ( 317 ) — — Foreign rate differential 1,181 — — Meals and entertainment 14 213 93 Stock -based compensation ( 8,387 ) ( 3,576 ) 106 162(m) Limitation 4,162 197 — Return to provision ( 1,127 ) 258 ( 26 ) Permanent adjustments 104 827 29 General business credits ( 3,761 ) ( 1,621 ) ( 152 ) Change in valuation allowance 6,031 110 215 Intercompany Profit in Inventory 701 — — Stock warrants — 696 — Total $ 845 $ — $ — As a result of losses incurred in the past, the Company has net operating loss (" NOL") carry-forwards that are available to offset future taxable income and subject to expiration rules and to Internal Revenue Code of 1986, as amended (“IRC”) §382. In general, IRC §382 may impact the amount of NOLs that can be utilized each year after certain ownership changes occur. An ownership change occurs, generally, if the percentage of stock of the loss corporation owned by one or more 5% shareholders has increased by more than 50 percentage points relative to the lowest percentage of stock of the loss corporation owned by the same 5% shareholders at any time during the testing period (generally, the three-year period preceding a testing date). Net operating losses and tax credit carryforwards as of December 31, 2021 are as follows: Amount Expiration Net operating losses, federal - Expiring $ 20,737 2031 - 2037 Net operating losses, federal - Indefinite 11,094 Indefinite Net operating losses, state 21,771 2031 - 2038 Net operating losses, foreign 9,206 2028 Tax credits, federal 7,488 2021 - 2031 Tax credits, state 4,162 Indefinite Pursuant to an IRC §382 limitation analysis performed by the Company, it was noted that an ownership change, as defined under IRC §382, occurred on March 29, 2018. Usage of NOL’s generated prior to March 29, 2018 will be limited to $ 3.0 million for calendar years 2019 through 2022 and $ 0.6 million from 2024 through 2039 for both federal and state purposes. Of the federal net operating loss and the state net operating loss carryforward amounts, $ 22.5 million and $ 22.0 million are subject to the IRC §382 limitation, respectively. There is not an IRC §382 limitation on the foreign NOLs. In the ordinary course of its business the Company incurs costs that, for tax purposes, are determined to be qualified research expenditures within the meaning of IRC §41 and are, therefore, eligible for the Increasing Research Activities credit under IRC §41. R&D credit carryovers generated prior to March 29, 2018 are limited under IRC §383 to $ 0.3 million a year for both federal and state purposes. The Company has adjusted the deferred tax assets related to Federal R&D credit carryover to account for any tax credits that will expire unused due to the IRC §383 limitations. As of December 31, 2021 and 2020 , the Company has total uncertain tax positions of $ 2.7 million and $ 0.9 million, respectively. The Company estimates that these liabilities would be reduced by $ 2.7 million and $ 0.9 million, respectively, from offsetting tax benefits associated with the correlative effects of net operating losses and other timing adjustments. The net amounts of all years, if not required, would favorably affect the Company's effective tax rate. No interest or penalties have been recorded related to the uncertain tax positions. A reconciliation of the beginning and ending balances of unrecognized tax benefits is as follows: Years Ended December 31, 2021 2020 2019 Balance at the beginning of the year $ 882 $ 1,091 $ 859 Additions based on tax positions related to the 1,352 287 458 Additions based on tax provisions related to 445 — — Deductions based on tax positions related to prior — ( 496 ) ( 226 ) Balance at the end of the year $ 2,679 $ 882 $ 1,091 It is not expected that there will be a significant change in uncertain tax position in the next 12 months . The Company is subject to U.S. federal and state income tax in multiple state jurisdictions, and various foreign jurisdictions . In the normal course of business, the Company is subject to examination by tax authorities. As of the date of the financial statements, there are no tax examinations in progress. The statute of limitations for tax years ended after December 31, 2018, December 31, 2017 and December 31, 2016 are open for federal, state and foreign tax purposes, respectively. CARES Act On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was signed into law in the U.S. to provide certain relief as a result of the COVID-19 pandemic. In addition, governments around the world have enacted or implemented various forms of tax relief measures in response to the economic conditions in the wake of COVID-19. As of December 31, 2021 , neither the CARES Act nor changes to income tax laws or regulations in other jurisdictions had a significant impact on our effective tax rate.

Retirement Plan

Retirement Plan	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Retirement Plan	14. Retirement Plan In December 2017, the Company adopted the Inari Medical, Inc. 401(k) Plan which allows eligible employees after one month of service to contribute pre-tax and Roth contributions to the plan, as allowed by law. The plan assets are held by Vanguard and the plan administrator is Ascensus Trust Company. Beginning in January 2021, the Company contributes a $ 1.00 match for every $ 1.00 contributed by a participating employee up to the greater of $ 3,000 or 4 % of eligible compensation under the plan, with such Company's contributions becoming fully vested immediately. For the year ended December 31, 2021, the Company recognized $ 3.3 million in matching contributions expense.

Net Income (Loss) Per Share

Net Income (Loss) Per Share	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	15. Net Income (Loss) Per Share The components of net income (loss) per share are as follows: Years Ended December 31, 2021 2020 2019 Numerator: Net income (loss) (in thousands) $ 9,840 $ 13,789 $ ( 1,192 ) Denominator: Weighted average number of common shares 49,815,914 32,033,827 5,887,542 Common stock equivalents from convertible — 12,490,452 — Common stock equivalents from outstanding 2,842,938 3,856,222 — Common stock equivalents from unvested RSUs 2,929,524 2,858,224 — Common stock equivalents from ESPP 5,783 - — Common stock equivalents from outstanding warrants — 191,194 — Common stock equivalents from restricted stock — 125,077 — Weighted average number of common shares 55,594,159 51,554,996 5,887,542 Net income (loss) per share: Basic $ 0.20 $ 0.43 $ ( 0.20 ) Diluted $ 0.18 $ 0.27 $ ( 0.20 ) The Company did no t have any anti-dilutive common stock equivalents for the years ended December 31, 2021 and 2020. The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share for the period presented below due to their anti-dilutive effect: Year Ended December 31, 2019 Convertible preferred stock 31,968,570 Common stock options 4,082,302 RSUs 2,867,326 Restricted stock subject to future vesting 397,199 Convertible preferred stock warrants 256,588 Common stock warrants 27,810 39,599,795

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
COVID-19 and CARES Act	COVID-19 and CARES Act The global healthcare system continues to face an unprecedented challenge as a result of the novel coronavirus, or COVID-19, situation and its impact. COVID-19 is having, and may continue to have, an adverse impact on significant aspects of the Company and the business, including the demand for products, business operations, and the ability to research and develop and bring to market new products and services. The business was most acutely affected by a decline in procedural volumes during the first half of 2020, and the results of 2021 reflect some recovery from these declines the Company experienced in 2020 as a result of COVID-19. However, with cases continuing to resurge in certain areas, and hospitals at capacity in some instances due to non-COVID-19 treatments, to the extent individuals and hospital systems de-prioritize, delay or cancel deferrable medical procedures, the Company’s business, cash flows, financial condition and results of operations may continue to be negatively affected. In response to the impact of COVID-19, the Company implemented a variety of measures to help manage through the impact and position it to resume operations quickly and efficiently once these restrictions were lifted. The Company continues to focus its efforts on the health and safety of patients, healthcare providers and employees, while executing its mission of transforming lives of venous thromboembolism (“VTE”) patients. However, the Company expects the COVID-19 pandemic may continue to negatively impact our future performance. The Taxpayer Certainty and Disaster Tax Relief Act of 2020 ("the Act"), was enacted on December 27, 2020. It was a response to continued market volatility and instability resulting from COVID-19 and includes provisions to support businesses in the form of loans, grants, and tax changes, among other types of relief. The Company has reviewed and incorporated the income tax changes included in the Act, including the deductibility of meals expenses previously not deductible for tax purposes. The Company does not believe there will be a material effect on the Company’s income tax provision. The Company has not and currently does not expect to apply for loans or grants expanded by the Act.
Basis of Preparation	Basis of Preparation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”).
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
Management Estimates	Management Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements may include, but are not limited to, collectability of receivables, recoverability of long-lived assets, valuation of inventory, fair value of common stock warrants, fair value of preferred stock warrant liabilities, fair value of stock options, recoverability of net deferred tax assets and related valuation allowance, and certain accruals. Estimates are based on historical experience and on various assumptions that the Company believes are reasonable under current circumstances. Actual results could differ materially from those estimates. Management periodically evaluates such estimates and assumptions, and they are adjusted prospectively based upon such periodic evaluation.
JOBS Act Accounting Election	JOBS Act Accounting Election The JOBS Act allows an emerging growth company to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. Effective December 31, 2021, the Company was no longer an “emerging growth company” within the meaning of the JOBS Act and can no longer take advantage of this extended transition period. Prior to December 31, 2021, the Company had elected to use this extended transition period and, as a result, our financial statements may not have been comparable to companies that comply with public company effective dates.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash The Company considers cash on hand, cash in demand deposit accounts including money market funds, and instruments with a maturity date of 90 days or less at date of purchase to be cash and cash equivalents. The Company maintains its cash, cash equivalent and restricted cash balances with banks. At times, the cash and cash equivalent balances may exceed federally insured limits. The Company does not believe that this results in any significant credit risk as the Company’s policy is to place its cash and cash equivalents in highly-rated financial institutions. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): December 31, 2021 2020 Cash and cash equivalents $ 92,752 $ 114,229 Restricted cash — 388 Total cash, cash equivalent and restricted cash $ 92,752 $ 114,617 Restricted cash as of December 31, 2020 consisted of a cash secured letter of credit in the amount of $ 338,000 representing collateral for the Company’s facility lease and a compensating balance of $ 50,000 to secure the Company’s corporate purchasing cards. In February 2021, the Company cancelled both the cash secured letter of credit and corporate purchasing card program and moved them both to its current bank, with no required cash security. Accordingly, as of December 31, 2021, the Company had no restricted cash.
Investments	Investments Investments in debt securities have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. The Company determines the appropriate classification of its investments in available-for-sale debt securities at the time of purchase. Available-for-sale securities with original maturities less than 12 months at the date of purchase are considered short-term investments. Available-for-sale debt securities with maturities greater than 12 months from the balance sheet date are classified as long-term investments on the consolidated balance sheets. Unrealized gains and losses are excluded from earnings and reported as a component of comprehensive income (loss). The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company’s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Realized gains and losses and declines in fair value judged to be other than temporary, if any, on marketable securities are included in other income (expenses), net on the consolidated statements of operations. The cost of investments sold is based on the specific-identification method. Interest on marketable securities is included in interest income.
Accounts Receivable, Net	Accounts Receivable, net Trade accounts receivable are recorded at the invoiced amount, net of any allowance for credit losses. The Company evaluates the expected credit losses of accounts receivable, considering historical credit losses, current customer-specific information and other relevant factors when determining the allowance. An increase to the allowance for credit losses results in a corresponding increase in selling, general and administrative ("SG&A") expenses. The Company charges off uncollectible receivables against the allowance when all attempts to collect the receivable have failed. The allowance for credit losses was $ 40,000 and $ 62,000 as of December 31, 2021 and 2020, respectively. Despite the Company’s efforts to minimize credit risk exposure, customers could be adversely affected if future economic and industry trends, including those related to COVID-19, change in such a manner as to negatively impact their cash flows. The full effects of COVID-19 on the Company’s customers are highly uncertain and cannot be predicted. As a result, the Company’s future collection experience can differ significantly from historical collection trends. If the Company’s clients experience a negative impact on their cash flows, it could have a material adverse effect on the Company’s results of operations and financial condition. Upon adoption of Accounting Standard Update (“ASU”) 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments , the Company did not recognize any adjustment to the beginning balance of retained earnings as of January 1, 2021, as the impact from the adoption was not material.
Inventories, Net	Inventories, net The Company values inventory at the lower of the actual cost to purchase or manufacture the inventory or net realizable value for such inventory. Cost, which includes material, labor and overhead costs, is determined on the first-in, first out method, or FIFO. The Company regularly reviews inventory quantities in process and on hand, and when appropriate, records a provision for obsolete and excess inventory. The Company writes down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements based on future demand and as compared to remaining shelf life. The estimate of excess quantities is subjective and primarily dependent on the Company’s estimates of future demand for a particular product. If the estimate of future demand is inaccurate based on actual sales, the Company may increase the write down for excess inventory for that component and record a charge to inventory impairment in the accompanying consolidated statement of operations and comprehensive income (loss).
Property and Equipment, net	Property and Equipment, net Property and equipment are stated at cost. Additions and improvements that extend the lives of the assets are capitalized while expenditures for repairs and maintenance are expensed as incurred. Depreciation is provided using the straight-line method over the estimated useful lives of the assets, ranging from three to seven years . Leasehold improvements are depreciated over the shorter of the useful life of the improvement or the lease term , including renewal periods that are reasonably assured. Upon sale or disposition of property and equipment, any gain or loss is included as other income (expense) in the accompanying consolidated statement of operations and comprehensive income (loss).
Right-of-use Assets and Lease Liabilities	Right-of-use Assets and Lease Liabilities The Company determines if an arrangement contains a lease at inception and determines the classification of the lease, as either operating or finance, at commencement. After the adoption of the new lease standard on January 1, 2021, right-of-use assets and lease liabilities are recorded based on the present value of future lease payments which factors in certain qualifying initial direct costs incurred as well as any lease incentives received. If an implicit rate is not readily determinable, the Company utilizes inputs from third-party lenders to determine the appropriate discount rate. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term. Lease terms may factor in options to extend or terminate the lease. The Company adheres to the short-term lease recognition exemption for all classes of assets (i.e. facilities and equipment). As a result, leases with an initial term of twelve months or less are not recorded on the balance sheet and are recognized on a straight-line basis over the lease term. In addition, for certain equipment leases, the Company accounts for lease and non-lease components, such as services, as a single lease component as permitted.
Deferred Initial Public Offering Costs	Public Offering Costs Costs related to public offerings, which consist of direct incremental legal, printing and accounting fees are deferred until the offering is completed. Upon completion of the offering, these costs are offset against the offering proceeds within the consolidated statements of stockholders' equity.
Impairment of Long-lived Assets	Impairment of Long-lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. The Company has not identified any such impairment losses to date.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s cash, cash equivalents and restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their liquidity or short maturities. The Company measures and records certain financial assets and liabilities at fair value on a recurring basis. U.S. GAAP provides a fair value hierarchy that distinguishes between (i) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (ii) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels. • Level 1—Adjusted quoted prices in active markets for identical assets or liabilities. • Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of assets or liabilities. See Note 3 for further information.
Convertible Preferred Stock Warrant Liability	Convertible Preferred Stock Warrant Liability The Company accounted for its freestanding warrants to purchase shares of the Company’s convertible preferred stock as liabilities at fair value upon issuance primarily because the preferred shares underlying the warrants contained contingent redemption features outside the control of the Company. The warrants were subject to remeasurement at each balance sheet date and any change in fair value was included as a component of other income (expense) in the condensed consolidated statements of operations and comprehensive income (loss). The carrying value of the warrants continued to be adjusted until the completion of the IPO, which occurred in May 2020. At that time, the preferred stock warrants were converted to common stock warrants and the related liability was adjusted to fair value and reclassified to additional paid-in capital, a component of stockholders’ equity.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers. Under ASC 606, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company sells its products primarily to hospitals in the United States utilizing the Company’s direct sales force. The Company recognizes revenue for arrangements where the Company has satisfied its performance obligation of shipping or delivering the product. For sales where the Company’s sales representative hand-deliver products directly to the hospitals, control of the products transfers to the customers upon such hand delivery. For sales where products are shipped, control of the products transfers either upon shipment or delivery of the products to the customer, depending on the shipping terms and conditions. Revenue from product sales is comprised of product revenue, net of product returns, administrative fees and sales rebates. Performance Obligation —The Company has revenue arrangements that consist of a single performance obligation, the shipping or delivery of the Company’s products. The satisfaction of this performance obligation occurs with the transfer of control of the Company’s product to its customers, either upon shipment or delivery of the product. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. The amount of revenue recognized is based on the transaction price, which represents the invoiced amount, net of administrative fees and sales rebates, where applicable. The Company provides a standard 30-day unconditional right of return period. The Company establishes estimated provisions for returns at the time of sale based on historical experience. Historically, the actual product returns have been immaterial to the Company’s consolidated financial statements. As of December 31, 2021 and 2020, the Company recorded $ 448,000 and $ 498,000 , respectively, of unbilled receivables, which are included in accounts receivable, net, in the accompanying consolidated balance sheets. Revenue for ClotTriever and FlowTriever products as a percentage of total revenue was derived as follow: Years Ended December 31, 2021 2020 2019 ClotTriever 32 % 37 % 38 % FlowTriever 68 % 63 % 62 % The Company offers payment terms to its customers of less than three months and these terms do not include a significant financing component. The Company excludes taxes assessed by governmental authorities on revenue-producing transactions from the measurement of the transaction price. The Company offers its standard warranty to all customers. The Company does not sell any warranties on a standalone basis. The Company’s warranty provides that its products are free of material defects and conform to specifications, and includes an offer to repair, replace or refund the purchase price of defective products. This assurance does not constitute a service and is not considered a separate performance obligation. The Company estimates warranty liabilities at the time of revenue recognition and records it as a charge to cost of goods sold. The warranty liability as of December 31, 2021 and 2020 and warranty cost recognized for the years ended December 31, 2021, 2020 and 2019 were not significant. Costs associated with product sales including commissions are recorded in SG&A expenses. The Company applies the practical expedient and recognizes commissions as expense when incurred because the amortization period is less than one year.
Cost of Goods Sold	Cost of Goods Sold Cost of goods sold consists primarily of the cost of raw materials, components, direct labor and manufacturing overhead. Overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management, including stock-based compensation. Cost of goods sold also includes depreciation expense for production equipment and certain direct costs such as shipping costs and royalty expense.
Advertising Costs	Advertising Costs Advertising costs are charged to operations as incurred. Advertising costs were $ 269,000 , $ 333,000 and $ 90,000 for the years ended December 31, 2021, 2020 and 2019 , respectively. Advertising costs are included in SG&A expenses in the accompanying consolidated statements of operations and comprehensive income (loss).
Research and Development	Research and Development Research and development costs are expensed as incurred and include the costs to design, develop, test, deploy and enhance new and existing products. Research and development costs also include expenses associated with the purchase of intellectual property relating to a particular research and development project that has no alternative future uses, clinical studies, registries and sponsored researches. These costs include direct salary and employee benefit related costs for research and development personnel, costs for materials used and costs for outside services.
Patent-related Expenditures	Patent-related Expenditures Expenditures related to patent research and applications, which are primarily legal fees, are expensed as incurred and are included in SG&A expenses in the accompanying consolidated statements of operations and comprehensive income (loss).
Stock-based Compensation	Stock-based Compensation The Company’s employee and non-employee share-based awards result in a cost that is measured at fair value on the awards’ grant date, based on the estimated number of awards that are expected to vest. Stock-based compensation is recognized over the service period.
Income Taxes	Income Taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Management assesses the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. As of December 31, 2021 and 2020, the net deferred tax assets have been fully offset by a valuation allowance. The Company recognizes uncertain income tax positions at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Changes in recognition or measurement are reflected in the period in which judgment occurs. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of provision for income taxes.
Foreign Currency Transaction	Foreign Currency Translation When the functional currencies of the Company’s foreign subsidiaries are currencies other than the U.S. dollar, the assets and liabilities of the foreign subsidiaries are translated into U.S. dollars at the exchange rate in effect on the balance sheet date. Income and expense items of the subsidiaries are translated into U.S. dollars at the average exchange rates prevailing during the period. Gains or losses from these translation adjustments are reported as a separate component of stockholders’ equity in accumulated other comprehensive income (loss) until there is a sale, or complete or substantially complete liquidation of the Company’s investment in the foreign subsidiaries, at which time the gains or losses will be realized and included in net income (loss). Transaction gains and losses are included in other income (expense) and have not been significant for the periods presented. The Company’s intercompany accounts are denominated in the functional currencies of the foreign subsidiaries. Gains and losses resulting from the remeasurement of intercompany transactions that the Company considers to be of a long-term investment nature are recorded in accumulated other comprehensive income or loss as a separate component of stockholders’ equity, while gains and losses resulting from the remeasurement of intercompany transactions from those foreign subsidiaries for which the Company anticipates settlement in the foreseeable future are recorded in the consolidated statement of operations.
Comprehensive Income (Loss)	Comprehensive Income (Loss) The Company’s comprehensive income (loss) is comprised of net income (loss) and changes in unrealized gain and losses on available-for-sale investments and gains or losses from foreign currency translation adjustments.
Net Income (Loss) per Share of Common Stock	Net Income (Loss) per Share of Common Stock Basic net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for potential dilutive common shares. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted average number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net income (loss) per share calculation, redeemable convertible preferred stock and warrants, and common stock options are potentially dilutive securities. For the years the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential dilutive common shares would have been anti-dilutive. The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. The shares of the Company’s convertible preferred stock participate in any dividends declared by the Company and are therefore considered to be participating securities.
Segment Reporting	Segment Reporting Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its Chief Executive Officer. The Company has determined it operates in one segment - the development and commercialization of innovative and minimally invasive mechanical thrombectomy devices to treat thromboembolism in the venous system. Geographically, the Company sells primarily to hospitals in the United States. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance.
Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements	Recently Adopted Accounting Pronouncements In February 2017, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASC 842”), as amended, which requires lessees to recognize “right of use” assets and liabilities for all leases with terms of more than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASC842 requires additional quantitative and qualitative financial statement note disclosures about the leases, significant judgments made in accounting for those leases and amounts recognized in the financial statements about those leases. The Company adopted the requirement of ASC 842 effective January 1, 2021 and elected the modified retrospective method for all lease arrangements with a cumulative-effect adjustment as of January 1, 2021. Results for reporting periods beginning on or after January 1, 2021 are presented under ASC 842, while prior period amounts were not adjusted and are reported in accordance with the Company’s historic accounting under ASC 840, Leases. For leases that commenced before the effective date of ASC 842, the Company elected the transition package of three practical expedients permitted within ASC 842, which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. The Company also elected the hindsight practical expedient, which permits the use of hindsight when determining lease term and impairment of right-of-use assets. Further, the Company elected a short-term lease exception policy, permitting the Company to not apply the recognition requirements of this standard to short-term leases (i.e., leases with terms of 12 months or less) and an accounting policy to account for lease and non-lease components as a single component for certain classes of assets. The Company determines if an arrangement is a lease at inception. As a lessee, right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company does not have any outstanding debt or committed credit facilities, the Company estimates the incremental borrowing rate based on prevailing financial market conditions, and management judgment. Operating lease right-of-use assets also include any lease payments made at or before lease commencement and exclude any lease incentives received. The lease terms used to calculate the right-of-use asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense, while the expense for finance leases is recognized as amortization expense and interest expense using the accelerated interest method of recognition. As a result of adopting ASC 842 as of January 1, 2021, the Company recorded an operating lease right-of-use asset of approximately $ 1.2 million and related operating lease liability of approximately $ 1.3 million based on the present value of the future lease payments on the date of adoption. There was no cumulative-effect adjustment recorded to retained earnings upon adoption. Adopting ASC 842 did not have a material impact on the Company’s condensed consolidated statements of operations and cash flows. See Note 7, Commitments and Contingencies, for further discussion of the Company’s adoption of ASC 842 and related disclosures. In December 2019, the FASB issued ASU 2019-12, Income Taxes – Simplifying the Accounting for Income Taxes , which simplifies the accounting for income taxes by clarifying and amending existing guidance related to the recognition of franchise tax, the evaluation of a step-up in the tax basis of goodwill and the effects of enacted changes in tax laws or rates in the effective tax rate computation, among other clarifications. ASU 2019-12 is effective for annual periods beginning after December 15, 2020, including interim periods within those fiscal years, and early adoption is permitted. The Company adopted this guidance effective January 1, 2021 and the adoption of this standard did not have a material impact on its consolidated financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting , which expands guidance on accounting for share-based payment awards, which includes share-based payment transactions for acquiring goods and services from nonemployees and aligns the accounting for share-based payments for employees and non-employees. The Company adopted this guidance effective January 1, 2020. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments , which changes the impairment model for most financial assets. The new model uses a forward-looking expected loss method, which will generally result in earlier recognition of allowances for losses. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. This standard provides guidance regarding methodologies and disclosures related to expected credit losses. The guidance became effective for the Company on December 31, 2021 when the Company no longer qualified for emerging growth company status. The Company adopted this guidance effective January 1, 2021. The adoption or this guidance did not have a material impact on the Company's consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): December 31, 2021 2020 Cash and cash equivalents $ 92,752 $ 114,229 Restricted cash — 388 Total cash, cash equivalent and restricted cash $ 92,752 $ 114,617
Schedule of Revenue for Products as Percentage of Total Revenue	Revenue for ClotTriever and FlowTriever products as a percentage of total revenue was derived as follow: Years Ended December 31, 2021 2020 2019 ClotTriever 32 % 37 % 38 % FlowTriever 68 % 63 % 62 %

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities Measured at Fair Value	The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of December 31, 2021 and 2020 (in thousands): December 31, 2021 Level 1 Level 2 Level 3 Aggregate Fair Value Financial Assets Cash and cash equivalents: Money market mutual funds $ 48,595 $ — $ — $ 48,595 Total included in cash and cash equivalents 48,595 — — 48,595 Investments: U.S. Treasury securities 44,322 — — 44,322 Corporate debt securities and commercial paper — 39,026 — 39,026 Total included in short-term investments 44,322 39,026 — 83,348 U.S. Treasury securities included in long-term investments 3,983 — — 3,983 Total assets $ 96,900 $ 39,026 $ — $ 135,926 December 31, 2020 Level 1 Level 2 Level 3 Aggregate Fair Value Financial Assets Cash and cash equivalents: Money market mutual funds $ 1,034 $ — $ — $ 1,034 U.S. Treasury securities 33,996 — — 33,996 Total included in cash and cash equivalents 35,030 — — 35,030 Investments: U.S. Treasury securities 24,992 — — 24,992 U.S. Government agencies — 24,989 — 24,989 Total included in short-term investments 24,992 24,989 — 49,981 Total assets $ 60,022 $ 24,989 $ — $ 85,011
Schedule of Change in the Fair Value of the Warrant Liability	The change in the fair value of the warrant liability is summarized below (in thousands): Years Ended December 31, 2020 2019 Beginning balance $ 1,169 $ 212 Change in fair value of warrant liability 3,317 957 Conversion of preferred stock warrants to common ( 4,486 ) — Ending balance $ — $ 1,169

Cash Equivalents and Short-Te_2

Cash Equivalents and Short-Term Investments (Tables)	12 Months Ended
	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Summary of Cash Equivalents and Short-Term Investments	The following is a summary of the Company’s cash equivalents and investments as of December 31, 2021 and 2020 (in thousands): December 31, 2021 Amortized Cost Basis Unrealized Gain Unrealized Loss Fair Value Financial Assets Cash and cash equivalents: Money market mutual funds $ 48,595 $ — $ — $ 48,595 Total included in cash and cash equivalents 48,595 — — 48,595 Investments: U.S. Treasury securities 44,349 — ( 27 ) 44,322 Corporate debt securities and commercial paper 39,012 14 — 39,026 Total included in short-term investments 83,361 14 ( 27 ) 83,348 U.S. Treasury securities included in long-term investments 3,993 — ( 10 ) 3,983 Total assets $ 135,949 $ 14 $ ( 37 ) $ 135,926 December 31, 2020 Amortized Cost Basis Unrealized Gain Unrealized Loss Fair Value Financial Assets Cash and cash equivalents: Money market mutual funds $ 1,034 $ — $ — $ 1,034 U.S. Treasury securities 33,996 — — 33,996 Total included in cash and cash equivalents 35,030 — — 35,030 Investments: U.S. Treasury securities 24,991 1 — 24,992 U.S. Government agencies 24,986 3 — 24,989 Total included in short-term investments 49,977 4 — 49,981 Total assets $ 85,007 $ 4 $ — $ 85,011 The Company regularly reviews the changes to the rating of its debt securities and reasonably monitors the surrounding economic conditions to assess the risk of expected credit losses. As of December 31, 2021 , the risk of expected credit losses was not significant.

Inventories, Net (Tables)

Inventories, Net (Tables)	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Inventories, Net	Inventories are net of reserves totaling $ 285,000 and $ 264,000 as of December 31, 2021 and 2020, respectively, and consist of the following (in thousands): December 31, 2021 2020 Raw materials $ 5,763 $ 2,607 Work-in-process 1,490 787 Finished goods 13,800 7,203 $ 21,053 $ 10,597

Property and Equipment. net (Ta

Property and Equipment. net (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consist of the following (in thousands): December 31, 2021 2020 Manufacturing equipment $ 7,408 $ 4,003 Leasehold improvements 4,712 1,737 Computer software 100 128 Furniture and fixtures 3,044 363 Computer hardware 2,864 980 Assets in progress 3,124 2,320 21,252 9,531 Accumulated depreciation ( 4,781 ) ( 2,033 ) $ 16,471 $ 7,498

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of total lease cost	Total lease cost for the year ended December 31, 2021 are as follows (in thousands): Year Ended Operating lease cost $ 1,568 Short-term lease cost 200 Variable lease cost 473 Total lease costs $ 2,241
Schedule of Future Minimum Commitments	Future minimum lease payments under operating leases liabilities as of December 31, 2021 are as follows (in thousands): Year ending December 31: Amount 2022 $ 2,542 2023 2,163 2024 2,234 2025 2,295 2026 2,361 Thereafter 39,536 Total lease payments 51,131 Less imputed interest ( 21,925 ) Total lease liabilities 29,206 Less: lease liabilities - current portion ( 802 ) Lease liabilities - noncurrent portion $ 28,404

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Deferred Financing Costs	As of December 31, 2021 and 2020, costs incurred directly related to debt are presented in other assets and are being amortized over the three-year life of the Credit Agreement on the straight-line basis as follows (in thousands): December 31, 2021 2020 Deferred financing costs $ 430 $ 430 Accumulated amortization ( 191 ) ( 47 ) Unamortized deferred financing costs $ 239 $ 383

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of Warrants Issued and Outstanding	The following table summarizes the changes in accumulated balances of other comprehensive income (loss), net of tax, for the years ended December 31, 2021 and 2020 (in thousands): Unrealized Gain (Loss) om Investments Foreign Currency Translation Accumulated Other Comprehensive Income (Loss) Balance, January 1, 2020 $ — $ — $ — Other comprehensive income 4 — 4 Balance, December 31, 2020 4 — 4 Other comprehensive loss ( 27 ) ( 379 ) ( 406 ) Balance, December 31, 2021 $ ( 23 ) $ ( 379 ) $ ( 402 )
Schedule of Fair Value of Preferred Warrants Determined Using Black Scholes Option Pricing Model	The fair value of the Preferred Warrants was determined using the Black Scholes option pricing model with the following assumptions: May 21, 2020 (1) December 31, 2019 Series A Series B Series A Series B Expected volatility 51.10 % 50.00 % 41.40 % 39.80 % Preferred stock fair value (per share) $ 19.00 $ 19.00 $ 5.88 $ 5.94 Dividend yield 0.00 % 0.00 % 0.00 % 0.00 % Risk free interest rates 0.17 % 0.53 % 1.58 % 1.83 % Expected remaining term in years 1.55 5.94 - 6.86 1.95 6.33 - 7.25 (1) Date the Company's registration statement on Form S-1 was declared effective.

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Stock Option Activity	A summary of stock option activity under the 2011 Plan for the years ended December 31, 2021 is as follows (intrinsic value in thousands): Number of Weighted Weighted Weighted Intrinsic Outstanding , December 31, 2018 2,688,527 $ 0.39 $ 0.31 8.95 $ 190 Granted 1,901,837 1.48 1.19 Exercised ( 409,893 ) 0.31 0.26 560 Cancelled ( 98,169 ) 0.40 0.34 Outstanding , December 31, 2019 4,082,302 0.90 0.74 8.76 22,667 Granted 305,494 7.47 3.73 Exercised ( 851,190 ) 0.55 0.50 49,413 Cancelled ( 99,821 ) 8.39 3.62 Outstanding , December 31, 2020 3,436,785 1.36 0.98 8.05 295,331 Exercised ( 806,008 ) 1.08 0.83 73,299 Cancelled ( 56,423 ) 2.17 1.36 Outstanding , December 31, 2021 2,574,354 $ 1.43 $ 1.02 7.07 $ 231,286 Vested and exercisable at December 31, 2021 1,598,546 $ 1.06 $ 0.78 6.88 $ 144,203 Vested and expected to vest at December 31, 2021 2,526,814 $ 1.40 $ 1.00 7.06 $ 227,074
Schedule of Estimated Fair Value of Options and Restricted Stock Units Grant on Date of Grant	The fair value of each option grant under the 2011 Plan was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: Years Ended December 31, 2020 2019 Expected volatility 40.60 % 53.5 % - 93.4 % Weighted-average volatility 40.60 % 83.24 % Common stock fair value (per share) $ 7.88 - $ 9.05 $ 0.59 -$ 6.15 Dividend yield 0.00 % 0.00 % Risk free interest rates 1.46 % - 1.68 % 1.67 % - 2.44 % Expected remaining term in years 5.90 - 6.07 5.02 - 7.00
Summary of RSU Activity	RSU activities under the 2011 Plan is set forth below (intrinsic value in thousands): Number of Weighted Outstanding, December 31, 2018 — $ — Granted 2,867,326 0.17 Outstanding, December 31, 2019 2,867,326 0.17 Outstanding, December 31, 2020 2,867,326 0.17 Vested ( 96,658 ) 0.17 Cancelled ( 57,994 ) 0.17 Outstanding, December 31, 2021 2,712,674 $ 0.17 RSU activity under the 2020 Plan is set forth below (intrinsic value in thousands): Number of Weighted Outstanding, December 31, 2019 — $ — Granted 227,963 58.68 Vested ( 1,199 ) 51.41 Cancelled ( 4,200 ) 51.41 Outstanding , December 31, 2020 222,564 58.86 Granted 515,880 98.98 Vested ( 99,758 ) 78.15 Cancelled ( 27,481 ) 86.41 Outstanding , December 31, 2021 611,205 $ 88.34
Schedule of Total Compensation Cost for All Share-Based Payment Arrangements Recognized	Total compensation cost for all share-based payment arrangements recognized, including $ 2,386,000 and $ 560,000 of stock-based compensation expense related to the Employee Stock Purchase Plan for the years ended December 31, 2021 and 2020, respectively, was as follows (in thousands): Years Ended December 31, 2021 2020 2019 Cost of goods sold $ 815 $ 155 $ 52 Research and development 2,214 592 99 Selling, general and administrative 22,419 2,777 354 Total share-based compensation expenses $ 25,448 $ 3,524 $ 505
2020 Employee Stock Purchase Plan
Schedule of Estimated Fair Value of Options and Restricted Stock Units Grant on Date of Grant	The fair value of the ESPP shares is estimated using the Black-Scholes option pricing model. Years Ended December 31, 2021 2020 Expected term (in years) 0.5 0.5 Expected volatility 51.47 %- 51.91 % 49.23 % Dividend yield 0.00 % 0.00 % Risk free interest rate 0.06 %- 0.08 % 0.11 %
Restricted Stock Units
Schedule of Estimated Fair Value of Options and Restricted Stock Units Grant on Date of Grant	The following assumptions were used to calculate the fair value of these RSUs in the Monte Carlo simulation model at the grant date: Year Ended December 31, 2019 Expected term (in years) 4.00 Expected volatility 50.00 % Dividend yield 0.00 % Risk free interest rate 2.41 % T

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Provision (Benefit) for Income Taxes	The Company's income tax provision is summarized as follows (in thousands): Years Ended December 31, 2021 2020 2019 Income (loss) before provision for income taxes: United States $ 18,301 $ 14,541 $ ( 1,192 ) Foreign ( 7,616 ) ( 752 ) — Income (loss) before income taxes $ 10,685 $ 13,789 $ ( 1,192 ) Current tax expense: State $ 832 $ — $ — Foreign 13 — — Total current tax expense 845 — — Total provision for income taxes $ 845 $ — $ — Provision for income taxes as a percentage 7.9 % 0.0 % 0.0 %
Schedule of Tax Effects of Significant Items Comprising Company's Deferred Taxes	The tax effects of significant items comprising the Company’s deferred taxes are as follows: December 31, 2021 2020 Deferred tax assets Inventory $ 778 $ 97 Intangible asset basis 2,390 1,475 Accrued employee compensation 1,028 547 Net operating losses and capital 8,918 8,033 Credit carryforwards 7,750 2,379 Equity compensation 1,511 358 Operating leases 7,432 — Others 44 64 Total deferred tax assets $ 29,851 $ 12,953 Deferred tax liabilities Fixed asset basis $ ( 2,810 ) $ ( 1,069 ) Right-of-use assets ( 9,138 ) — Other liabilities ( 7 ) ( 18 ) Total deferred tax liabilities $ ( 11,955 ) $ ( 1,087 ) Valuation allowance $ ( 17,896 ) $ ( 11,866 ) Net deferred tax assets $ — $ —
Schedule of Reconciliation of Effective Tax Rate of (Provision) Benefit for Income Taxes from Federal Statutory Rate	The effective tax rate of the Company’s provision for income taxes differs from the federal statutory rate as follows: Years Ended December 31, 2021 2020 2019 Statutory rate $ 2,244 $ 2,896 $ ( 265 ) State taxes, net of federal benefit ( 317 ) — — Foreign rate differential 1,181 — — Meals and entertainment 14 213 93 Stock -based compensation ( 8,387 ) ( 3,576 ) 106 162(m) Limitation 4,162 197 — Return to provision ( 1,127 ) 258 ( 26 ) Permanent adjustments 104 827 29 General business credits ( 3,761 ) ( 1,621 ) ( 152 ) Change in valuation allowance 6,031 110 215 Intercompany Profit in Inventory 701 — — Stock warrants — 696 — Total $ 845 $ — $ —
Schedule of Net Operating Losses And Tax Credit Carryforwards	Net operating losses and tax credit carryforwards as of December 31, 2021 are as follows: Amount Expiration Net operating losses, federal - Expiring $ 20,737 2031 - 2037 Net operating losses, federal - Indefinite 11,094 Indefinite Net operating losses, state 21,771 2031 - 2038 Net operating losses, foreign 9,206 2028 Tax credits, federal 7,488 2021 - 2031 Tax credits, state 4,162 Indefinite
Summary of Reconciliation of Beginning and Ending Balances of Unrecognized Tax Benefits	A reconciliation of the beginning and ending balances of unrecognized tax benefits is as follows: Years Ended December 31, 2021 2020 2019 Balance at the beginning of the year $ 882 $ 1,091 $ 859 Additions based on tax positions related to the 1,352 287 458 Additions based on tax provisions related to 445 — — Deductions based on tax positions related to prior — ( 496 ) ( 226 ) Balance at the end of the year $ 2,679 $ 882 $ 1,091

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Components of Net Income (loss) per Share	The components of net income (loss) per share are as follows: Years Ended December 31, 2021 2020 2019 Numerator: Net income (loss) (in thousands) $ 9,840 $ 13,789 $ ( 1,192 ) Denominator: Weighted average number of common shares 49,815,914 32,033,827 5,887,542 Common stock equivalents from convertible — 12,490,452 — Common stock equivalents from outstanding 2,842,938 3,856,222 — Common stock equivalents from unvested RSUs 2,929,524 2,858,224 — Common stock equivalents from ESPP 5,783 - — Common stock equivalents from outstanding warrants — 191,194 — Common stock equivalents from restricted stock — 125,077 — Weighted average number of common shares 55,594,159 51,554,996 5,887,542 Net income (loss) per share: Basic $ 0.20 $ 0.43 $ ( 0.20 ) Diluted $ 0.18 $ 0.27 $ ( 0.20 )
Schedule of Outstanding Potentially Dilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share	The Company did no t have any anti-dilutive common stock equivalents for the years ended December 31, 2021 and 2020. The following outstanding potentially dilutive common stock equivalents have been excluded from the calculation of diluted net loss per share for the period presented below due to their anti-dilutive effect: Year Ended December 31, 2019 Convertible preferred stock 31,968,570 Common stock options 4,082,302 RSUs 2,867,326 Restricted stock subject to future vesting 397,199 Convertible preferred stock warrants 256,588 Common stock warrants 27,810 39,599,795

Organization - Additional Infor

Organization - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	May 31, 2020	Dec. 31, 2019	Dec. 31, 2021	May 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Net proceeds from IPO				$ 163,000	$ 0	$ 164,361	$ 0
Underwriters' discounts and commissions	$ 12,600
Offering costs	$ 3,700
Offering cost incurred		$ 1,400
Preferred stock converted into common stock	31,968,570			31,968,570
Preferred stock, conversion basis			31,968,570		Upon the completion of the IPO, all shares of Series A, B, and C redeemable convertible preferred stock then outstanding were converted into 31,968,570 shares of common stock on a one-to-one basis.
Converted into warrants to purchase common stock	256,588		256,588	256,588	256,588
Common stock, shares authorized			300,000,000		300,000,000	300,000,000
Common stock, Par value			$ 0.001		$ 0.001	$ 0.001
Preferred stock, shares authorized			10,000,000		10,000,000	10,000,000
Preferred stock, par value			$ 0.001		$ 0.001	$ 0.001
IPO
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Stock issued	9,432,949
Public offering price	$ 19			$ 19
Common stock, shares authorized	300,000,000			300,000,000
Common stock, Par value	$ 0.001			$ 0.001
Preferred stock, shares authorized	10,000,000			10,000,000
Preferred stock, par value	$ 0.001			$ 0.001
Over-allotment Option
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of stock, shares issued				1,230,384

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details)	12 Months Ended
	Dec. 31, 2021USD ($)Segment	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Jan. 01, 2021USD ($)	Oct. 31, 2020USD ($)
Summary of Significant Accounting Policies [Line Items]
Restricted cash as collateral for facility lease	$ 0	$ 338,000
Restricted cash to secure corporate purchasing cards	0	50,000
Allowance for doubtful accounts	$ 40,000,000	62,000,000
Number of operating segments | Segment	1
Operating lease right-of-use assets	$ 44,909,000	0		$ 1,200,000	$ 42,200,000
Operating lease liability	29,206,000			$ 1,300,000	$ 28,600,000
Accumulated deficit	$ (17,583,000)	(27,423,000)
Accounting Standards Update 201912 Member
Summary of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted	true
Change in accounting principle, accounting standards update, adoption date	Jan. 1, 2021
Change in accounting principle, accounting standards update, immaterial effect	true
Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2016-02
Summary of Significant Accounting Policies [Line Items]
Accumulated deficit	$ 0
SG&A Expenses
Summary of Significant Accounting Policies [Line Items]
Advertising costs	269,000	333,000	$ 90,000
Accounts Receivable, Net
Summary of Significant Accounting Policies [Line Items]
Unbilled receivables	$ 448,000,000	498,000
Leasehold Improvements
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives	shorter of the useful life of the improvement or the lease term
Cash Secured Letter of Credit
Summary of Significant Accounting Policies [Line Items]
Restricted cash as collateral for facility lease		$ 338,000
Maximum
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives of assets	7 years
Minimum
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives of assets	3 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Cash and cash equivalents	$ 92,752	$ 114,229
Restricted cash	0	388
Total cash, cash equivalent and restricted cash	$ 92,752	$ 114,617	$ 24,027	$ 21,884

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Revenue for Products as Percentage of Total Revenue (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
ClotTriever Products
Revenue from External Customer [Line Items]
Percentage of total revenue	32.00%	37.00%	38.00%
FlowTriever Products
Revenue from External Customer [Line Items]
Percentage of total revenue	68.00%	63.00%	62.00%

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Level 1
Assets
Total included in cash and cash equivalents	$ 48,595	$ 35,030
Total included in short-term investments	44,322	24,992
Assets Fair Value Disclosure, Total	96,900	60,022
Level 1 | US Treasury Securities
Assets
Total included in cash and cash equivalents		33,996
Total included in short-term investments	44,322	24,992
Level 1 | US Treasury Securities | Long-Term Investments
Assets
Total included in short-term investments	3,983
Level 1 | U.S. Government Agencies
Assets
Total included in short-term investments		0
Level 1 | Corporate Debt Securities and Commercial Paper
Assets
Total included in short-term investments	0
Level 1 | Money Market Mutual Funds
Assets
Total included in cash and cash equivalents	48,595	1,034
Level 2
Assets
Total included in cash and cash equivalents	0	0
Total included in short-term investments	39,026	24,989
Assets Fair Value Disclosure, Total	39,026	24,989
Level 2 | US Treasury Securities
Assets
Total included in cash and cash equivalents		0
Total included in short-term investments	0	0
Level 2 | US Treasury Securities | Long-Term Investments
Assets
Total included in short-term investments	0
Level 2 | U.S. Government Agencies
Assets
Total included in short-term investments		24,989
Level 2 | Corporate Debt Securities and Commercial Paper
Assets
Total included in short-term investments	39,026
Level 2 | Money Market Mutual Funds
Assets
Total included in cash and cash equivalents	0	0
Level 3
Assets
Total included in cash and cash equivalents	0	0
Total included in short-term investments	0	0
Assets Fair Value Disclosure, Total	0	0
Level 3 | US Treasury Securities
Assets
Total included in cash and cash equivalents		0
Total included in short-term investments	0	0
Level 3 | US Treasury Securities | Long-Term Investments
Assets
Total included in short-term investments	0
Level 3 | U.S. Government Agencies
Assets
Total included in short-term investments		0
Level 3 | Corporate Debt Securities and Commercial Paper
Assets
Total included in short-term investments	0
Level 3 | Money Market Mutual Funds
Assets
Total included in cash and cash equivalents	0	0
Fair Value Measurements Recurring
Assets
Total included in cash and cash equivalents	48,595	35,030
Total included in short-term investments	83,348	49,981
Assets Fair Value Disclosure, Total	135,926	85,011
Fair Value Measurements Recurring | US Treasury Securities
Assets
Total included in cash and cash equivalents		33,996
Total included in short-term investments	44,322	24,992
Fair Value Measurements Recurring | US Treasury Securities | Long-Term Investments
Assets
Total included in short-term investments	3,983
Fair Value Measurements Recurring | U.S. Government Agencies
Assets
Total included in short-term investments		24,989
Fair Value Measurements Recurring | Corporate Debt Securities and Commercial Paper
Assets
Total included in short-term investments	39,026
Fair Value Measurements Recurring | Money Market Mutual Funds
Assets
Total included in cash and cash equivalents	$ 48,595	$ 1,034

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details)	Dec. 31, 2021USD ($)
Fair Value Disclosures [Abstract]
Fair value, assets, Level 1 to Level 2 transfers, amount	$ 0
Fair value, assets, Level 2 to Level 1 transfers, amount	0
Fair value, liabilities, Level 1 to Level 2 transfers, amount	0
Fair value, liabilities, Level 2 to Level 1 transfers, amount	$ 0

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Change in the Fair Value of the Warrant Liability (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Beginning balance	$ 1,169	$ 212
Change in fair value of warrant liability	3,317	957
Conversion of preferred stock warrants to common stock warrants upon the closing of the IPO	(4,486)	0
Ending balance	$ 0	$ 1,169

Cash Equivalents and Short-Te_3

Cash Equivalents and Short-Term Investments - Summary of Cash Equivalents and Short-Term Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Investment Income Reported Amounts By Category [Line Items]
Cash Equivalents and Short-Term Investments, Amortized Cost Basis	$ 135,949	$ 85,007
Cash Equivalents and Short-Term Investments, Unrealized Gain	14	4
Cash Equivalents and Short-Term Investments, Unrealized Loss	(37)	0
Cash Equivalents and Short-Term Investments, Fair Value	135,926	85,011
Short-term investments	83,348	49,981
Cash And Cash Equivalents
Schedule Of Investment Income Reported Amounts By Category [Line Items]
Cash Equivalents and Short-Term Investments, Amortized Cost Basis	48,595	35,030
Cash Equivalents and Short-Term Investments, Unrealized Gain	0	0
Cash Equivalents and Short-Term Investments, Unrealized Loss	0	0
Cash Equivalents and Short-Term Investments, Fair Value	48,595	35,030
Cash And Cash Equivalents | US Treasury Securities
Schedule Of Investment Income Reported Amounts By Category [Line Items]
Cash Equivalents and Short-Term Investments, Amortized Cost Basis		33,996
Cash Equivalents and Short-Term Investments, Unrealized Gain		0
Cash Equivalents and Short-Term Investments, Unrealized Loss		0
Cash Equivalents and Short-Term Investments, Fair Value		33,996
Short Term investments
Schedule Of Investment Income Reported Amounts By Category [Line Items]
Cash Equivalents and Short-Term Investments, Amortized Cost Basis	83,361	49,977
Cash Equivalents and Short-Term Investments, Unrealized Gain	14	4
Cash Equivalents and Short-Term Investments, Unrealized Loss	(27)	0
Cash Equivalents and Short-Term Investments, Fair Value	83,348	49,981
Short Term investments | US Treasury Securities
Schedule Of Investment Income Reported Amounts By Category [Line Items]
Cash Equivalents and Short-Term Investments, Amortized Cost Basis	44,349	24,991
Cash Equivalents and Short-Term Investments, Unrealized Gain	0	1
Cash Equivalents and Short-Term Investments, Unrealized Loss	(27)	0
Cash Equivalents and Short-Term Investments, Fair Value	44,322	24,992
Short Term investments | Corporate Debt Securities and Commercial Paper
Schedule Of Investment Income Reported Amounts By Category [Line Items]
Cash Equivalents and Short-Term Investments, Amortized Cost Basis	39,012
Cash Equivalents and Short-Term Investments, Unrealized Gain	14
Cash Equivalents and Short-Term Investments, Unrealized Loss	0
Cash Equivalents and Short-Term Investments, Fair Value	39,026
Short Term investments | U.S. Government Agencies
Schedule Of Investment Income Reported Amounts By Category [Line Items]
Cash Equivalents and Short-Term Investments, Amortized Cost Basis		24,986
Cash Equivalents and Short-Term Investments, Unrealized Gain		3
Cash Equivalents and Short-Term Investments, Unrealized Loss		0
Cash Equivalents and Short-Term Investments, Fair Value		24,989
Long-Term Investments | US Treasury Securities
Schedule Of Investment Income Reported Amounts By Category [Line Items]
Cash Equivalents and Short-Term Investments, Amortized Cost Basis	3,993
Cash Equivalents and Short-Term Investments, Unrealized Gain	0
Cash Equivalents and Short-Term Investments, Unrealized Loss	(10)
Cash Equivalents and Short-Term Investments, Fair Value	3,983
Money Market Mutual Funds | Cash And Cash Equivalents
Schedule Of Investment Income Reported Amounts By Category [Line Items]
Cash Equivalents and Short-Term Investments, Amortized Cost Basis	48,595	1,034
Cash Equivalents and Short-Term Investments, Unrealized Gain	0	0
Cash Equivalents and Short-Term Investments, Unrealized Loss	0	0
Cash Equivalents and Short-Term Investments, Fair Value	$ 48,595	$ 1,034

Inventories, Net - Additional I

Inventories, Net - Additional Information (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventory reserves	$ 285,000	$ 264,000

Inventories, Net - Schedule of

Inventories, Net - Schedule of Inventories, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 5,763	$ 2,607
Work in process	1,490	787
Finished goods	13,800	7,203
Inventory, net	$ 21,053	$ 10,597

Property and Equipment. net - S

Property and Equipment. net - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 21,252	$ 9,531
Accumulated depreciation	(4,781)	(2,033)
Property and equipment, net	16,471	7,498
Manufacturing Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	7,408	4,003
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	4,712	1,737
Computer Software
Property Plant And Equipment [Line Items]
Property and equipment, gross	100	128
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	3,044	363
Computer Hardware
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,864	980
Assets In Progress
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 3,124	$ 2,320

Property and Equipment. net - A

Property and Equipment. net - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Depreciation expense	$ 3,034,000	$ 1,385,000	$ 614,000
Loss on retirement of assets	(69,000)	(237,000)	(119,000)
Capitalized implementation cost, net	$ 785,000
Capitalized implementation cost, amortization method	The capitalized costs are amortized on a straight-line basis over the non-cancelable contract terms, generally three years.
Capitalized implementation cost, amortization period	3 years
Capitalized implementation cost, current	$ 391,000,000	228,000,000
Accounting Standards Update 2016-02 | Revision of Prior Period, Accounting Standards Update, Adjustment
Property Plant And Equipment [Line Items]
Tenant improvement reclassified to other assets		1,556,000
Other Assets Member
Property Plant And Equipment [Line Items]
Capitalized implementation cost, current	55,000,000	0
SG&A Expenses
Property Plant And Equipment [Line Items]
Depreciation expense	2,367,000	1,039,000	511,000
Capitalized implementation cost, amortization	222,000	100,000	16,000
Cost of Goods Sold
Property Plant And Equipment [Line Items]
Depreciation expense	$ 667,000	$ 346,000	$ 103,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	Mar. 31, 2019ExtensionPeriod	Oct. 31, 2020USD ($)ExtensionPeriod	Dec. 31, 2021USD ($)Warehouse	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Jan. 01, 2021USD ($)
Lessee Lease Description [Line Items]
Operating lease, number of extension options | ExtensionPeriod		2
Prepaid lease payments		$ 2,800,000
Operating lease right-of-use assets		42,200,000	$ 44,909,000	$ 0		$ 1,200,000
Operating lease liability		$ 28,600,000	$ 29,206,000			$ 1,300,000
Operating lease, remaining lease term		235 months	7 months
Weighted average incremental borrowing rate			6.00%
Tenant Allowance		$ 13,500,000
Tenant allowance related to prepaid lease payments		3,700,000
Cash paid for amounts included in the measurement of lease liabilities			$ 14,600,000
Research and development			51,018,000	18,399,000	$ 7,220,000
Accrued Expenses And Other Current Liabilities			10,737,000	2,593,000
Other long-term liability			1,416,000	$ 0
Research and Development Expense
Lessee Lease Description [Line Items]
Research and Development Expense Accrued			4,200,000
Accrued Expenses And Other Current Liabilities			2,800,000
Other long-term liability			1,400,000
Letter of Credit
Lessee Lease Description [Line Items]
Secured debt		$ 1,500,000
Equipment
Lessee Lease Description [Line Items]
Operating lease right-of-use assets			106,000
Operating lease liability			$ 107,000
Operating lease, remaining lease term			42 months
Licensed Technology
Lessee Lease Description [Line Items]
Research and development			$ 4,200,000
Maximum
Lessee Lease Description [Line Items]
Operating lease, term of contract	12 months
Irvine, California
Lessee Lease Description [Line Items]
Operating lease, term of contract	5 years	10 years
Operating lease, expiration date	Sep. 30, 2024
Operating lease, number of extension options | ExtensionPeriod	2
Option to extend, operating lease, term	5 years	5 years
Operating lease, rent holiday concession period	1 month
Operating lease, description			The lease includes a one-month rent holiday concession and escalation clauses for increased rent over the lease term.
Operating lease right-of-use assets			$ 367,000
Operating lease liability			413,000
Cash paid for amounts included in the measurement of lease liabilities			13,800,000
Lake Forest, California and Irvine, California
Lessee Lease Description [Line Items]
Operating lease right-of-use assets			33,000
Operating lease liability			$ 34,000
Operating lease, remaining lease term			6 months
Number of additional warehouse spaces | Warehouse			2
Oak Canyon
Lessee Lease Description [Line Items]
Operating lease right-of-use assets			$ 44,400,000
Operating lease liability			$ 28,700,000

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Commitments (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Jan. 01, 2021	Dec. 31, 2020	Oct. 31, 2020
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2022	$ 2,542
2023	2,163
2024	2,234
2025	2,295
2026	2,361
Thereafter	39,536
Total lease payments	51,131
Less imputed interest	(21,925)
Total lease liabilities	29,206	$ 1,300		$ 28,600
Less: lease liabilities - current portion	(802)		$ 0
Lease liabilities - noncurrent portion	$ 28,404		$ 0

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of total lease cost (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Lessee, Lease, Description [Line Items]
Operating lease cost	$ 1,568
Short-term lease cost	200
Total variable lease cost	473
Leasehold Improvements
Lessee, Lease, Description [Line Items]
Total lease cost	$ 2,241

Concentrations - Additional Inf

Concentrations - Additional Information (Details)	12 Months Ended
	Dec. 31, 2021CustomerVendor	Dec. 31, 2020CustomerVendor	Dec. 31, 2019CustomerVendor
Revenue | Customer Concentration Risk
Concentration Risk [Line Items]
Number of customers | Customer	0	0	0
Revenue | Customer Concentration Risk | Minimum
Concentration Risk [Line Items]
Concentration risk	10.00%	10.00%	10.00%
Purchases | Supplier Concentration Risk
Concentration Risk [Line Items]
Number of vendor | Vendor	0	0	0
Purchases | Supplier Concentration Risk | Minimum
Concentration Risk [Line Items]
Concentration risk	10.00%	10.00%	10.00%
Accounts Receivable | Customer Concentration Risk
Concentration Risk [Line Items]
Number of customers | Customer	0	0
Accounts Receivable | Customer Concentration Risk | Minimum
Concentration Risk [Line Items]
Concentration risk	10.00%	10.00%
Accounts Payable | Supplier Concentration Risk
Concentration Risk [Line Items]
Number of vendor | Vendor	0	0
Accounts Payable | Supplier Concentration Risk | Minimum
Concentration Risk [Line Items]
Concentration risk	10.00%	10.00%

Related Party - Additional Info

Related Party - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
MRI The Hoffman Group
Related Party Transaction [Line Items]
Due to related parties	$ 0	$ 0
Inceptus
Related Party Transaction [Line Items]
Reimbursement of expenses and milestone and administration fees			$ 139,000
Administration fee	116,000	95,000
Royalty expense	$ 769,000	488,000	103,000
Inceptus | Minimum
Related Party Transaction [Line Items]
Related party transaction, rate	1.00%
Royalty quarterly fee	$ 1,000
Inceptus | Maximum
Related Party Transaction [Line Items]
Related party transaction, rate	1.50%
Recruiting Services | MRI The Hoffman Group | OperatingExpense
Related Party Transaction [Line Items]
Development expenses incurred	$ 369,000	$ 427,000	$ 380,000

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($)	1 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Number of Letter of Credit	2	1
SB Credit Facility
Debt Instrument [Line Items]
Credit facility					$ 40,000,000
SB Credit Facility | Maximum
Debt Instrument [Line Items]
Percentage of eligible accounts receivable to borrow, repay and re-borrow debt		80.00%
Eligible accounts receivable to borrow, repay and re-borrow debt	$ 15,000,000
SB Credit Facility | Minimum
Debt Instrument [Line Items]
Annual interest rate of term loan		5.00%
SB Credit Facility | Revolving Line of Credit
Debt Instrument [Line Items]
Credit facility	$ 15,000,000
SB Credit Facility | Term Loan
Debt Instrument [Line Items]
Credit facility				$ 10,000,000	$ 25,000,000
Maturity date of credit facility	2024-12
Credit facility, frequency of periodic payment	monthly
Interest only payments period		2021-12
SB Credit Facility | Term Loan | Prime Rate
Debt Instrument [Line Items]
Term loan variable interest rate		0.50%
SB Credit Facility | Term Loan | Minimum
Debt Instrument [Line Items]
Annual interest rate of term loan	5.50%
SB Credit Facility | Term Loan Fully Funded on Closing Date
Debt Instrument [Line Items]
Credit facility	$ 15,000,000
SB Credit Facility | Term Loan to be Available Through December 2020
Debt Instrument [Line Items]
Credit facility		$ 10,000,000
Bank of America Credit Facility | Credit Agreement
Debt Instrument [Line Items]
Line of credit closing fee	150,000,000
Legal and other fees	$ 280,000,000
Line of credit facility covenant terms	The Credit Agreement contains certain customary covenants and events of default, including: payment defaults, breaches of any representation, warranty or covenants, judgment defaults, cross defaults to certain other contracts, certain events with respect to governmental approvals if such events could cause a material adverse change, a material impairment in the perfection or priority of the lender's security interest or in the value of the collateral, a material adverse change in the business, operations, or condition of us or any of our subsidiaries, and a material impairment of the prospect of repayment of the loans. Upon the occurrence of an event of default, a default increase in the interest rate of an additional 2.0% could be applied to the outstanding loan balance and the lender could declare all outstanding obligations immediately due and payable and take such other actions as set forth in the loan and security agreement.
Bank of America Credit Facility | Senior Secured Revolving Credit Facility | Credit Agreement
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity			$ 30,000,000
Percentage of accounts receivable available to borrow			85.00%
Cash pledged under credit agreement	$ 0	0
Line of Credit Facility, Remaining Borrowing Capacity	$ 28,200,000	28,500,000
Interest on loans outstanding payable	monthly
Debt maturity month and year	2023-09
Bank of America Credit Facility | Senior Secured Revolving Credit Facility | Federal Funds Rate | Credit Agreement
Debt Instrument [Line Items]
Term loan variable interest rate	0.50%
Debt instrument, description of variable rate basis	the Federal funds rate plus 0.50%
Bank of America Credit Facility | Senior Secured Revolving Credit Facility | LIBOR | Credit Agreement
Debt Instrument [Line Items]
Term loan variable interest rate	1.00%
Debt instrument, description of variable rate basis	the LIBOR rate based upon an interest period of 30 days plus 1.00%
Bank of America Credit Facility | Senior Secured Revolving Credit Facility | Maximum | Credit Agreement
Debt Instrument [Line Items]
Term loan variable interest rate	1.50%
Unused line fee at annual rate	0.375%
Bank of America Credit Facility | Senior Secured Revolving Credit Facility | Minimum | Credit Agreement
Debt Instrument [Line Items]
Term loan variable interest rate	1.00%
Unused line fee at annual rate	0.25%
Bank of America Credit Facility | Letter of Credit Subline Facility
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 5,000,000
Percentage of fee on average daily stated amount of outstanding letter of credit	2.25%
Percentage of fronting fee on stated amount of each letter of credit outstanding	0.125%
Letters of credit outstanding amount	$ 1,800,000	$ 1,500,000
Bank of America Credit Facility | LIBOR Loans | Senior Secured Revolving Credit Facility | LIBOR | Credit Agreement
Debt Instrument [Line Items]
Term loan variable interest rate	2.00%
Bank of America Credit Facility | LIBOR Loans | Senior Secured Revolving Credit Facility | Maximum | LIBOR | Credit Agreement
Debt Instrument [Line Items]
Term loan variable interest rate	2.50%

Debt - Schedule of Deferred Fin

Debt - Schedule of Deferred Financing Costs (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Deferred financing costs	$ 430	$ 430
Accumulated amortization	(191)	(47)
Unamortized deferred financing costs	$ 239	$ 383

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock - Schedule of Redeemable Convertible Preferred Stock (Details)	May 31, 2020shares
Temporary Equity [Line Items]
Shares Outstanding	31,968,570

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock - Additional Information (Details)	May 31, 2020shares
Temporary Equity Disclosure [Abstract]
Redeemable convertible preferred stock, shares outstanding	31,968,570
Preferred stock converted into common stock	31,968,570

Stockholders' Equity- Additiona

Stockholders' Equity- Additional Information (Details) - $ / shares	Dec. 31, 2021	Dec. 31, 2020	Nov. 30, 2020	Jun. 30, 2020	May 31, 2020
Class Of Stock [Line Items]
Redeemable convertible preferred stock, shares outstanding					31,968,570
Preferred stock converted into common stock					31,968,570
Common stock, shares authorized	300,000,000	300,000,000
Common stock, Par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	0	0
Preferred stock, Par value	$ 0.001	$ 0.001
Number of warrants outstanding	0	0
Converted into warrants to purchase common stock	256,588				256,588
Class of warrant exercised for cash			179,558	77,030
Number of common stock shares issued upon exercise of preferred stock warrants			174,776	74,723
Common Stock Warrants
Class Of Stock [Line Items]
Class of warrant exercised for cash				27,810

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Fair Value of Preferred Warrants Determined Using Black Scholes Option Pricing Model (Details)		May 21, 2020$ / shares		Dec. 31, 2019$ / shares
Series A
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Preferred stock fair value (per share)		$ 19	[1]	$ 5.88
Series B
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Preferred stock fair value (per share)		$ 19	[1]	$ 5.94
Expected Volatility | Series A
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement input		51.10	[1]	41.40
Expected Volatility | Series B
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement input		50	[1]	39.80
Dividend Yield | Series A
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement input	[1]	0
Dividend Yield | Series B
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement input		0	[1]	0
Risk Free Interest Rates | Series A
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement input		0.17	[1]	1.58
Risk Free Interest Rates | Series B
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement input		0.53	[1]	1.83
Expected Remaining Term | Series A
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected remaining term in years		1 year 6 months 18 days	[1]	1 year 11 months 12 days
Expected Remaining Term | Series B | Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected remaining term in years		5 years 11 months 8 days	[1]	6 years 3 months 29 days
Expected Remaining Term | Series B | Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected remaining term in years		6 years 10 months 9 days	[1]	7 years 3 months
[1]	Date the Company's registration statement on Form S-1 was declared effective.

Stockholders Equity - Schedule

Stockholders Equity - Schedule of Accumulated Balances of Other Comprehensive Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 200,254	$ (39,144)	$ (39,446)
Other Comprehensive Income (Loss)	(406)	4	0
Balance	239,209	200,254	(39,144)
Foreign Currency Translation
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other Comprehensive Income (Loss)	(379)
Balance	(379)
Unrealized Gain (Loss) on Investments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	4	0
Other Comprehensive Income (Loss)	(27)	4
Balance	(23)	4	0
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	4	0
Other Comprehensive Income (Loss)	(406)	4
Balance	$ (402)	$ 4	$ 0

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional Information (Details) - USD ($)	1 Months Ended			3 Months Ended	5 Months Ended	12 Months Ended
	Jul. 31, 2021	May 31, 2020	Mar. 31, 2019	Mar. 31, 2020	May 21, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividends declared						$ 0
Dividends paid						0
Stock-based compensation expense						25,448,000	$ 3,524,000	$ 505,000
Compensation costs related to all non-vested awards to be recognized in future						$ 47,329,000,000
Non vested stock awards, expected remaining weighted average period						3 years 1 month 6 days
Deferred Income Tax Expense (Benefit)						$ 10,300	4,900
Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock purchased under ESPP						85,049
SG&A Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense						$ 22,419,000	2,777,000	$ 354,000
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield								0.00%
Award vesting period			4 years
Stock-based compensation expense					$ 0
Restricted stock units, vested	96,658					4,993
Risk free interest rate								2.41%
Restricted Stock Units | SG&A Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Dividend yield						0.00%
Stock-based compensation expense						$ 500
Weighted-average volatility						51.90%
Share Price						$ 105.54
Risk free interest rate						0.10%
Restricted Stock Units | General and Administrative Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 8,300,000
Restricted Stock Units | IPO | SG&A Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense							$ 159,000,000
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense						$ 2,386,000,000
2020 Incentive Award Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved for future issuance				3,468,048
Percentage of annual increase in shares reserved for issuance on capital stock outstanding at year end				3.00%
Number of shares available for issuance						4,670,472
Number of shares granted						515,880	227,963
Restricted stock units, vested						99,758	1,199
Total fair value of RSUs vested						$ 17,700,000	$ 80,000,000
2020 Incentive Award Plan | Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period						4 years
Share-based compensation vesting rights, terms						The RSUs generally vest over a four-year period with straight-line vesting and a 25% one-year cliff or over a three-year period in equal amounts on a quarterly basis, provided the employee remains continuously employed with the Company
2020 Incentive Award Plan | Restricted Stock Units | SG&A Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense						$ 400
Restricted stock units, vested						8,947
2020 Incentive Award Plan | Employee Stock Purchase Plan | Share Based Compensation Award Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Cliff vesting, percentage						25.00%
2020 Incentive Award Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Term of award				10 years
2011 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved for future issuance						1,477,548
Dividend yield							0.00%	0.00%
Number of shares granted								2,867,326
Restricted stock units, vested						96,658
Total fair value of RSUs vested						$ 17,700,000	$ 80,000,000
Weighted-average volatility							40.60%	83.24%
2011 Equity Incentive Plan | Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares granted			2,867,326
2011 Equity Incentive Plan | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Price							$ 7.88	$ 0.59
2011 Equity Incentive Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Price							$ 9.05	$ 6.15
2020 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved for future issuance		990,870				1,398,337
Dividend yield						0.00%	0.00%
Stock-based compensation expense							$ 560,000,000
First offering start date		Aug. 1, 2020
First offering end date		Jan. 31, 2021
Percentage of purchase price on fair market value of common stock		85.00%
Risk free interest rate							0.11%
2020 Employee Stock Purchase Plan | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock purchased under ESPP						85,049	0

Equity Incentive Plans - Summar

Equity Incentive Plans - Summary of Stock Option Activity (Details) - 2011 Equity Incentive Plan - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Number of Awards
Number of Awards, Outstanding, Beginning balance	3,436,785	4,082,302	2,688,527
Number of Awards, Granted		305,494	1,901,837
Number of Awards, Exercised	(806,008)	(851,190)	(409,893)
Number of Awards, Cancelled	(56,423)	(99,821)	(98,169)
Number of Awards, Outstanding, Ending balance	2,574,354	3,436,785	4,082,302	2,688,527
Number of Awards, Vested and exercisable	1,598,546
Number of Awards, Vested and expected to vest	2,526,814
Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 1.36	$ 0.90	$ 0.39
Weighted Average Exercise Price, Granted		7.47	1.48
Weighted Average Exercise Price, Exercised	1.08	0.55	0.31
Weighted Average Exercise Price, Cancelled	2.17	8.39	0.40
Weighted Average Exercise Price, Outstanding, Ending balance	1.43	1.36	0.90	$ 0.39
Weighted Average Exercise Price, Vested and exercisable	1.06
Weighted Average Exercise Price, Vested and expected to vest	1.40
Weighted Average Fair Value
Weighted Average Fair Value, Outstanding, Beginning balance	0.98	0.74	0.31
Weighted Average Fair Value, Granted		3.73	1.19
Weighted Average Fair Value, Exercised	0.83	0.50	0.26
Weighted Average Fair Value, Cancelled	1.36	3.62	0.34
Weighted Average Fair Value, Outstanding, Ending balance	1.02	$ 0.98	$ 0.74	$ 0.31
Weighted Average Fair Value, Vested and exercisable	0.78
Weighted Average Fair Value, Vested and expected to vest	$ 1
Weighted Average Remaining Contractual Life (in years)
Weighted Average Remaining Contractual Life (in years), Outstanding	7 years 25 days	8 years 18 days	8 years 9 months 3 days	8 years 11 months 12 days
Weighted Average Remaining Contractual Life (in years), Vested and exercisable	6 years 10 months 17 days
Weighted Average Remaining Contractual Life (in years), Vested and expected to vest	7 years 21 days
Intrinsic Value
Intrinsic Value, Outstanding	$ 231,286	$ 295,331	$ 22,667	$ 190
Intrinsic Value, Exercised	73,299	$ 49,413	$ 560
Intrinsic Value, Vested and exercisable	144,203
Intrinsic Value, Vested and expected to vest	$ 227,074

Equity Incentive Plans - Schedu

Equity Incentive Plans - Schedule of Estimated Fair Value of Options and Restricted Stock Units Grant on Date of Grant (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility			50.00%
Dividend yield			0.00%
Expected remaining term in years			4 years
Risk free interest rate			2.41%
2011 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility		40.60%
Expected volatility, minimum			53.50%
Expected volatility, maximum			93.40%
Weighted-average volatility		40.60%	83.24%
Dividend yield		0.00%	0.00%
Risk free interest rates, minimum		1.46%	1.67%
Risk free interest rates, maximum		1.68%	2.44%
2011 Equity Incentive Plan | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock fair value (per share)		$ 7.88	$ 0.59
Expected remaining term in years		5 years 10 months 24 days	5 years 7 days
2011 Equity Incentive Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock fair value (per share)		$ 9.05	$ 6.15
Expected remaining term in years		6 years 25 days	7 years
2020 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility		49.23%
Expected volatility, minimum	51.47%
Expected volatility, maximum	51.91%
Dividend yield	0.00%	0.00%
Risk free interest rates, minimum	0.06%
Risk free interest rates, maximum	0.08%
Expected remaining term in years	6 months	6 months
Risk free interest rate		0.11%

Equity Incentive Plans - Summ_2

Equity Incentive Plans - Summary of RSU Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
2020 Incentive Award Plan
Number of Awards
Number of Awards, Outstanding, Beginning balance	222,564
Number of shares granted	515,880	227,963
Number of Awards, Vested	(99,758)	(1,199)
Number of Awards, Cancelled	(27,481)	(4,200)
Number of Awards, Outstanding, Ending balance	611,205	222,564
Weighted Average Fair Value
Weighted Average Fair Value, Outstanding, Beginning balance	$ 58.86	$ 0
Weighted Average Fair Value, Granted	98.98	58.68
Weighted Average Fair Value, Vested	78.15	51.41
Weighted Average Fair Value, Cancelled	86.41	51.41
Weighted Average Fair Value, Outstanding, Ending balance	$ 88.34	$ 58.86	$ 0
2011 Equity Incentive Plan
Number of Awards
Number of Awards, Outstanding, Beginning balance	2,867,326	2,867,326	0
Number of shares granted			2,867,326
Number of Awards, Vested	(96,658)
Number of Awards, Cancelled	(57,994)
Number of Awards, Outstanding, Ending balance	2,712,674	2,867,326	2,867,326
Weighted Average Fair Value
Weighted Average Fair Value, Outstanding, Beginning balance	$ 0.17	$ 0.17	$ 0
Weighted Average Fair Value, Granted			0.17
Weighted Average Fair Value, Vested	0.17
Weighted Average Fair Value, Cancelled	0.17
Weighted Average Fair Value, Outstanding, Ending balance	$ 0.17	$ 0.17	$ 0.17

Equity Incentive Plans - Sche_2

Equity Incentive Plans - Schedule of Total Compensation Cost for All Share-Based Payment Arrangements Recognized (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total compensation cost	$ 25,448	$ 3,524	$ 505
Cost of Goods Sold
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total compensation cost	815	155	52
Research and Development Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total compensation cost	2,214	592	99
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total compensation cost	$ 22,419	$ 2,777	$ 354

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provision (Benefit) for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
united states	$ 18,301	$ 14,541	$ (1,192)
Foreign	(7,616)	(752)	0
Income (loss) before income taxes	10,685	13,789	(1,192)
State	832	0	0
Foreign	13
Total current tax expense	845
Total Provision for income taxes	845	0	0
Net income (loss)	$ 9,840	$ 13,789	$ (1,192)
Provision for income taxes as a percentage of income (loss) before taxes	7.90%	0.00%	0.00%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Line Items]
Effective tax rate	7.90%	0.00%	0.00%
Total Provision for income taxes	$ 845,000	$ 0	$ 0
Increase in valuation allowance	$ 6,000
Operating loss carryforward description	As a result of losses incurred in the past, the Company has net operating loss ("NOL") carry-forwards that are available to offset future taxable income and subject to expiration rules and to Internal Revenue Code of 1986, as amended (“IRC”) §382. In general, IRC §382 may impact the amount of NOLs that can be utilized each year after certain ownership changes occur. An ownership change occurs, generally, if the percentage of stock of the loss corporation owned by one or more 5% shareholders has increased by more than 50 percentage points relative to the lowest percentage of stock of the loss corporation owned by the same 5% shareholders at any time during the testing period (generally, the three-year period preceding a testing date).
Operating loss carryforwards, limitations on use description	Pursuant to an IRC §382 limitation analysis performed by the Company, it was noted that an ownership change, as defined under IRC §382, occurred on March 29, 2018. Usage of NOL’s generated prior to March 29, 2018 will be limited to $3.0 million for calendar years 2019 through 2022 and $0.6 million from 2024 through 2039 for both federal and state purposes. Of the federal net operating loss and the state net operating loss carryforward amounts, $22.5 million and $22.0 million are subject to the IRC §382 limitation, respectively. There is not an IRC §382 limitation on the foreign NOLs.
Tax credit carryforward, limitations on use description	In the ordinary course of its business the Company incurs costs that, for tax purposes, are determined to be qualified research expenditures within the meaning of IRC §41 and are, therefore, eligible for the Increasing Research Activities credit under IRC §41. R&D credit carryovers generated prior to March 29, 2018 are limited under IRC §383 to $0.3 million a year for both federal and state purposes. The Company has adjusted the deferred tax assets related to Federal R&D credit carryover to account for any tax credits that will expire unused due to the IRC §383 limitations.
R&D credit carryovers, Limitation on use	$ 300,000
Total uncertain tax positions	2,679,000	882,000	$ 1,091,000	$ 859,000
Unrecognized tax benefits, decrease from offsetting and other timing adjustments	2,700,000	$ 900,000
Interest or penalties related to uncertain tax positions	$ 0
Significant change in unrecognized tax position, description	It is not expected that there will be a significant change in uncertain tax position in the next 12 months
Income tax examination, description	In the normal course of business, the Company is subject to examination by tax authorities. As of the date of the financial statements, there are no tax examinations in progress. The statute of limitations for tax years ended after December 31, 2018, December 31, 2017 and December 31, 2016 are open for federal, state and foreign tax purposes, respectively.
Federal
Income Tax Disclosure [Line Items]
Limitation on usage of NOL	$ 22,500,000
State
Income Tax Disclosure [Line Items]
Limitation on usage of NOL	22,000,000
Calendar Years 2019 Through 2022
Income Tax Disclosure [Line Items]
R&D credit carryovers, Limitation on use	3,000,000
Calendar Years 2024 Through 2029
Income Tax Disclosure [Line Items]
Limitation on usage of NOL	$ 600,000

Income Taxes - Schedule of Tax

Income Taxes - Schedule of Tax Effects of Significant Items Comprising Company's Deferred Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets
Inventory	$ 778	$ 97
Intangible asset basis	2,390	1,475
Accrued employee compensation	1,028	547
Net operating losses and capital loss carryforwards	8,918	8,033
Credit carryforwards	7,750	2,379
Equity compensation	1,511	358
Operating leases	7,432	0
Other	44	64
Total deferred tax assets	29,851	12,953
Deferred tax liabilities
Fixed Asset basis	(2,810)	(1,069)
Right-of-use assets	(9,138)	0
Other liabilities	(7)	(18)
Total deferred tax liabilities	(11,955)	(1,087)
Valuation allowance	(17,896)	(11,866)
Net deferred tax Assets	$ 0	$ 0

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Effective Tax Rate of (Provision) Benefit for Income Taxes from Federal Statutory Rate (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Statutory rate	$ 2,244	$ 2,896	$ (265)
State taxes, net of federal benefit	(317)	0	0
Foreign rate differential	1,181	0	0
Meals and entertainment	14	213	93
Stock -based compensation	(8,387)	(3,576)	106
162(m) Limitation	4,162	197	0
Return to provision	(1,127)	258	(26)
Permanent adjustments	104	827	29
General business credits	(3,761)	(1,621)	(152)
Change in valuation allowance	6,031	110	215
Intercompany Profit in Inventory	701	0	0
Stock warrants	0	696	0
Total	$ 845	$ 0	$ 0

Income Taxes - Schedule of Net

Income Taxes - Schedule of Net Operating Losses and Tax Credit Carryforwards (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Federal
Operating Loss Carryforwards [Line Items]
Net operating losses, Expiring, Amount	$ 20,737
Net operating losses, Amount	11,094
Tax credits, Amount	$ 7,488
Net operating losses, Expiration Years, Description	Indefinite
Federal | Earliest Tax Year
Operating Loss Carryforwards [Line Items]
Net operating losses, Expiration Years	2031
Tax credits, Expiration Years	2021
Federal | Latest Tax Year
Operating Loss Carryforwards [Line Items]
Net operating losses, Expiration Years	2037
Tax credits, Expiration Years	2031
State
Operating Loss Carryforwards [Line Items]
Net operating losses, Amount	$ 21,771
Tax credits, Amount	$ 4,162
Tax credits, Expiration Years, Description	Indefinite
State | Earliest Tax Year
Operating Loss Carryforwards [Line Items]
Net operating losses, Expiration Years	2031
State | Latest Tax Year
Operating Loss Carryforwards [Line Items]
Net operating losses, Expiration Years	2038
Foreign
Operating Loss Carryforwards [Line Items]
Net operating losses, Amount	$ 9,206
Net operating losses, Expiration Years	2028

Income Taxes - Summary of Recon

Income Taxes - Summary of Reconciliation of Beginning and Ending Balances of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Balance at the beginning of the year	$ 882	$ 1,091	$ 859
Additions based on tax positions related to the current year	1,352	287	458
Additions based on tax provisions related to prior years	445	0	0
Deductions based on tax positions related to prior years	0	(496)	(226)
Balance at the end of the year	$ 2,679	$ 882	$ 1,091

Retirement Plan - Additional In

Retirement Plan - Additional Information (Details)	12 Months Ended
	Dec. 31, 2021USD ($)
Defined Benefit Plan Disclosure [Line Items]
401 (k) Plan	us-gaap:QualifiedPlanMember
Employer contributions by plan participant	$ 1
Employee contributions by plan participant	$ 1
Participating employee eligible compensation	4.00%
Matching contribution expense recognized	$ 3,300,000
Maximum
Defined Benefit Plan Disclosure [Line Items]
Participating employee up to greater	$ 3,000

Net Income (Loss) Per Share - C

Net Income (Loss) Per Share - Computation of Net Income (Loss) per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Numerator:
Net income	$ 9,840	$ 13,789	$ (1,192)
Weighted average common shares used to compute net (loss) income per share
Basic	49,815,914	32,033,827	5,887,542
Common stock equivalents from convertible preferred stock	0	12,490,452	0
Common stock equivalents from outstanding warrants	0	191,194	0
Weighted average number of common shares outstanding - diluted	55,594,159	51,554,996	5,887,542
Earnings Per Share, Basic [Abstract]
Basic	$ 0.20	$ 0.43	$ (0.20)
Earnings Per Share, Diluted [Abstract]
Diluted	$ 0.18	$ 0.27	$ (0.20)
Common Stock Options
Weighted average common shares used to compute net (loss) income per share
Common stock equivalents	2,842,938	3,856,222
Unvested RSUs
Weighted average common shares used to compute net (loss) income per share
Common stock equivalents	2,929,524	2,858,224
ESPP
Weighted average common shares used to compute net (loss) income per share
Common stock equivalents	5,783	0	0
Restricted Stock
Weighted average common shares used to compute net (loss) income per share
Common stock equivalents	0	125,077

Net Income (Loss) Per Share - A

Net Income (Loss) Per Share - Additional Information (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share	0	0	39,599,795

Net Income (Loss) Per Share - S

Net Income (Loss) Per Share - Schedule of Outstanding Potentially Dilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	0	0	39,599,795
Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share			31,968,570
Common Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share			4,082,302
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share			2,867,326
Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share			397,199
Convertible Preferred Stock Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share			256,588
Common Stock Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share			27,810